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  1 
Introduction 
1. The need of a novel dermal delivery system 
1.1. Obstacles in dermal delivery 
The skin with its outer surface of 1.8 m2 is one of the largest human organs and protects the 
body against exogenous substances, damages by radiation, and other exposures [1]. In 
addition, it is easily accessible for drug delivery. Dermal delivery can be divided in transdermal 
and topical dermal delivery. Either applications have a systemic (transdermal) or local and 
regional restricted (dermal) effects. Advantage of transdermal delivery is the partially 
avoidance of the first-pass effect [2]. Dermal delivery has advantages such as targeted delivery 
and reduction of systemic side effects. Thus, topical dermal delivery is perfectly suited for 
treating of skin diseases like psoriasis or dermatosis but also for prevention of skin aging and 
pollution induced damages. This led to an estimated revenue of about 19 billion USD only for 
skin applications in the OTC pharmaceutical market 2018 [3]. 
Actives are supposed to show certain physicochemical properties enabling penetration and 
efficacy in dermal delivery. According to the “Rule of 5” [4] low molecular weights (<500 kDa) 
and a log P below 5 are physicochemical pre-requisites since most penetration depends on 
passive diffusion regardless the route (intercellular, transcellular, and through hair 
follicles) [5-7]. This physicochemical properties are mostly applicable for actives with a certain 
water solubility – leading to high penetration rates and good dermal performance [8]. 
Many drugs and actives – especially from natural origin – are poorly soluble in water and 
sometimes simultaneously poorly soluble in lipophilic media. In case of new chemical entities 
in the pharmaceutical industry 40% of them are practically insoluble in water [9], leading to 
an insufficient penetration and bioavailability [10; 11]. 
Therefore, novel approaches are needed to address bioavailability issues. This results in 





1.2. Relevant delivery systems for dermal application 
Liposomes are considered as one of the major inventions in dermal delivery. They were 
invented in 1961 [12], entered the cosmetic market in 1986 and shortly after the 
pharmaceutical market [13]. Liposomes are vesicles consisting of a phospholipid bilayer in an 
aqueous phase. Lipophilic actives can be dissolved in the phospholipid layer and thus their 
solubility in the formulation is increased [14]. 
Another system are microemulsions, a thermodynamically stable system with lipophilic and 
hydrophilic domains in the nanometer range. They are able to increase the saturation 
solubility of actives in their composition of lipophilic and hydrophilic domains stabilized with 
a high surfactant concentration. Advantage of the microemulsions is their thermodynamic 
stability. After application, the formulation spontaneously disperses into an emulsion due to 
contact with water (e.g. due to the skin or the gastrointestinal tract). Thereby the active is 
solubilized [15]. In case of dermal application, the reached supersaturation state leads to an 
increased diffusion pressure into the skin [13]. However, the high surfactant concentration 
and potential active instability limits dermal application. 
At the beginning of the 1990s invention of the next major delivery system followed with the 
solid lipid nanoparticles (SLN) [16]. They avoided the disadvantages of previous delivery 
systems such as possible active degradation and high surfactant concentrations. Meanwhile 
these solid lipid nanoparticles are developed in the 3rd generation called “smartLipids®” after 
solid lipid nanoparticles (1st generation) and nanostructured lipid carriers (NLC, 
2nd generation) [17]. Principle behind these systems is the incorporation of actives into a lipid 
matrix staying solid at skin temperature. For SLN one lipid is melted, mixed with an aqueous 
stabilizer solution and high pressure homogenized. Solid lipid particles in the nanometer range 
are obtained after cooling. They are dispersed and stabilized in the aqueous phase. In case of 
NLC and smartLipids® a more complex lipid matrix is used resulting in higher loading capacities 
and increased physical stability [18]. Moreover, release can be easily modified by the lipid 
composition [18]. Depending on the stabilizer and used excipients these suspensions can be 
applied by various administration routes, even intravenous [19]. Identically to polymeric 
nanoparticles, controlled release is inherent in these systems because of the solid particle 
structure which releases the active [19]. Further the actives are protected against 
degradation. In dermal application they form an occlusive film on the skin which enhance 
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penetration and repair the “brick and mortar” structure of the stratum corneum [20]. The NLC 
entered the cosmetic market in 2005. Examples of products are Nanorepair (Dr. Rimpler, 
Germany), products in the line IOPE (AmorePacific, Korea), and swiss cellular white (la prairie, 
Switzerland) [21]. 
Nanocrystals were reported as delivery system by Liversidge et al. [22]. They show high 
potential to reduce solubility problems of BCS (biopharmaceutical classification system) II (low 
solubility, high permeability) and BCS IV (low solubility, low permeability) classified 
actives [23]. They consist of crystals in the nanometer range (<1000 nm), stabilized by a 
surfactant in an aqueous or non-aqueous dispersion medium. Dissolution pressure of a solid 
crystal increases at the solid/liquid interface with decreasing particle size. This process is 
similar to the increasing vapor pressure of a decreasing liquid droplet on the liquid/gas 
interface. It can be described by the Kelvin equation [24]. Outstanding advantage of 
nanocrystals/submicron particles is the increased saturation solubility. Additionally, the 
dissolution velocity is enhanced according to the Noyes-Whitney equation [25]. Decreasing 
particle size leads to an increase of the total surface area which is responsible for this increase. 
Both effects result in a subsequently improved penetration and hence better 
bioavailability [25]. Furthermore, the increased surface of nanocrystals enhances the 
adhesiveness compared to microcrystals. This is responsible for further increase in 
efficacy [26]. Application is possible by several administration routes including intravenous, 
pulmonary, oral and dermal [25; 27]. Production of nanocrystals can be performed by top 
down or bottom up methods, whereby the top-down methods are more efficient and result 
in higher concentrated suspensions [28]. If 50% of particles (number distribution) are below 
100 nm “nano” declaration is mandatory due to the European Union regulation 
EC No 1223/2009. Thus particle size, especially in cosmetics, is mostly above 100 nm to avoid 
the “nano” declaration because of consumer reluctance. However, apart from that definition 
of “nano” all particles between 1 and 1000 nm are physically in the nanometer-range and take 
advantage of their properties. For better differentiation, particles between 100 and 1000 nm 
can be described as submicron particles. They possess the properties of nanoparticles but are 
no nanoparticles according the legal definition. 
Since the last two decades a newer approach attracts more attention. Solid dispersions are 
able to prevent re-crystallization of amorphous actives [29]. Actives in the amorphous state 
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show many advantages compared to their crystalline counterpart such as higher solubility and 
better dissolution behavior (cf. Chapter 1.3) [30; 31]. To prepare solid dispersions several 
technologies are available. Widely known is the distribution of the active in a polymer 
matrix [32]. Re-crystallization can be inhibited. However, use of polymer matrices is limited 
by regulatory aspects (e.g. toxicology of monomers, excipients used for polymerization) and 
the lack of predictable miscibility and stability of the solid dispersions [29]. Further, the 
saturation solubility potential of amorphous actives decreases in a mixture with a 
polymer [33]. Increasing concerns towards polymers appeared in recent years, especially 
towards the use in cosmetic products due to the microplastic discussion. 
Besides polymer matrices, mesoporous silica attracted increasing attention as matrix since 
about 2005. Amorphous stability is ensured by the defined properties of the used silica 
(cf. Chapter 1.4.1). However, up to now most of the research focus on oral dosage forms. 
Similar to nanostructured lipid carrier and nanocrystals the following step is to transfer this 
technology to other administration routes such as dermal [34]. 
1.3. Properties and opportunities of amorphous actives 
A crystal has per definition a crystal lattice which is, caused by its low internal energy, 
responsible for a high stability of the molecules in the crystal lattice. Disadvantage is the 
energy needed for dissolution. In contrast, the amorphous state is similar to the liquid state 
of an active. Differently to the liquid state the molecules are immobile to each other. Thus, 
amorphous substances are also called “solidified melts”. Special feature of the amorphous 
state is the high internal energy due to the absence of the crystal lattice. The molecules are in 
a non-ordered orientation. This results in an easier access to the molecules in media and 
requires less energy to dissolve the molecules.  
The most obvious benefit of using the amorphous state in drug delivery systems is the high 
internal energy. The saturation solubility and dissolution velocity increase manifolds 
compared to the crystalline low energy form. Dissolution is facilitated by the high internal 
energy (absence of a crystalline lattice) and easier solvation of the non-ordered molecule 
structure. Thus, there is a high potential to increase the bioavailability of poorly soluble actives 
by using the solubility and dissolution advantages of the amorphous state. 
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Problem is the tendency of the molecules to reach a more stable state – the crystal lattice –
which can lead to spontaneous re-crystallization. Occurring re-crystallization reduces the 
highly soluble amount of amorphous active. Dissolution velocity and saturation solubility 
decrease after solution of the amorphous part, limit the solubility advantage and changes 
dosing. Moreover, crystallization nuclei might introduce complete crystallization and 
terminate thereby the solubility advantage of the amorphous state. This limits the general use 
of amorphous actives and leads to the need of suitable delivery systems, to stabilize this state. 
1.4. Dermal formulation solution for amorphous actives – smartPearls 
The advantage of amorphous actives (cf. Chapter 1.3) making them also interesting to 
overcome problems in dermal delivery (cf. Chapter 1.1). The increased saturation solubility of 
the amorphous active leads to a higher concentration gradient between the formulation and 
the skin. Penetration of poorly soluble actives and hence their bioavailability are improved. 
Mesoporous silica as stabilizing matrix are preferred compared to polymer 
matrices (cf. Chapter 1.2). Amorphous solid dispersions using mesoporous silica are a 
promising approach to improve the dermal bioavailability of poorly soluble actives.  
Since most of the research is focusing on oral application more research towards dermal 
application is needed. To differentiate between oral and dermal application, the dermal 
delivery system is called smartPearls. This delivery system was submitted as patent application 
in 2014 [34]. Data of superiority in dermal delivery of amorphous actives stabilized in 
mesoporous silica were published shortly after [35]. Amorphous stability of several actives 
(e.g. hesperidin, rutin, cyclosporine A) were proven for several years and published from 
Jin N. et al. [36]. Increased active penetration due to the smartPearls system compared to 
previous dermal delivery systems were demonstrated by tape stripping studies [36]. 
Maximum application concentrations were defined (cf. Chapter 1.5.2). However, several 
issues are still unresolved relating silica selection, appropriate loading methods, industrial 
feasibility, and implementation. 
1.4.1. Silica structures as stabilizing matrix 
Mesoporous silica are defined as porous particles with pores between 2 and 50 nm. Mostly 
they are highly porous having pore volumes of 0.1 up to 2.0 mL and surface areas of 100 up 
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to 1000 m2/g. In pharmaceutical applications mesoporous silica are widely used as functional 
and non-functional excipients.  
Beside their use as filler for tableting, they are used as carrier for liquid substances because 
of their good adsorption properties both for aqueous and lipophilic media. Due to their use as 
functional excipients, interactions between used actives and silica were discovered. Based on 
this, a new application area appeared for the silica as amorphous active delivery carrier [37].  
Stabilization of amorphous actives with mesoporous silica particles were already reported in 
the 1970s [38; 39]. A major concern was the stability of the amorphous state [37]. After 
invention of ordered mesoporous silica structures in the 1990s [40] the researchers showed 
more interest in them as amorphous stabilizing matrix. Ordered mesoporous silica show 
defined pore size with narrow distribution and pore structure [41-43]. With the advantage of 
defined properties, the stability concerns declined. Thus, ordered mesoporous silica particles 
are widely used in pharmaceutical research for stabilization of amorphous actives. This helped 
to understand which impact pore parameters have on amorphous stabilization [44]. 
On the contrary, up to now ordered mesoporous silica are not regulatory accepted which is a 
hurdle for fast realization of products. Additionally, ordered mesoporous silica are about 
10 times more expensive than non-ordered mesoporous silica as they show a narrower pore 
size distribution. However, since non-ordered mesoporous silica are used for decades in 
pharmaceutical applications, they are available in a huge variety with different properties 
depending on the respective need [37]. The industry has lots of practical experience because 
of the present use. This and the price make them reasonable for development of novel 
delivery systems. In consequence, several researchers are working with non-ordered 
mesoporous silica showing similar potential of amorphous active stabilization [44-48]. In 
addition, non-ordered silica are generally GRAS proven, dermally applicable, and most 
important being accepted in cosmetic formulations.  
Re-crystallization of the amorphous state is prevented by incorporation into the mesopores 
of silica. Surface interactions and/or size restrictions are discussed as main reasons for 
stabilization of the amorphous active [37]. Hempel et al. recognize surface interaction 
between active and silica as the main stabilizing effect [46; 49]. The high impact of the surface 
is underlined by research regarding surface modification to improve the stabilization 
effects [50]. However, too high active carrier binding affinity can lead adversely to an 
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unintended retarded and/or incomplete release. In addition, modification of the surface leads 
to excipients which are regulatorily not accepted and need a separate approval. Industrially 
desired is of course one fitting solution for as much actives as possible. Therefore, chemical 
modification of the silica would rather diminish the field of application than increasing it. Since 
pore size and surface area are connected to each other they are both supposed as essential 
for stabilization of the amorphous active [33; 45]. 
Pore size is frequently discussed to hinder re-crystallization due to space restriction [51-53]. 
Investigated pore sizes reach mostly from 2 to 25 nm. Smallest useable pore size for effective 
stabilization of the amorphous state is mostly defined by the molecule size [49]. The maximum 
possible pore size is depending on the smallest possible crystal, which can be formed if the 
pore size is larger than 12 times the molecule size [54]. Thus, a pore size molecule ratio of 12 
should not be exceeded. By use of non-ordered silica, the polydisperse pore size distribution 
must be considered. Re-crystallization can theoretically already occur if few pores are above 
the maximum molecule pore size ratio. 
The nano-dispersion of the active in the silica and the eased wettability, due to the hydrophilic 
silica structure, are discussed to enhance the solubility [51]. This assumption is supported by 
the exceeding saturation solubility of cyclosporine A incorporated in mesoporous silica 
compared to respective amorphous nanoparticles [36]. Better understanding of the 
mechanism is desired to increase the predictability of increase in saturation solubility.  
Besides that, several other issues need further investigation. The optimum pore parameters 
in dependency of the active are one of it. Also, more research towards the impact of the 
loading method on the active deposition in the mesoporous structure is needed. Furthermore, 
it must be investigated, how the deposition influences the stability and release of the active.  
1.4.2. Loading methods 
Loading of the silica particles can be performed by several approaches, divided into solvent 
and solvent free methods. Obviously, solvent free methods are preferable since solvents are 
a cost factor and the proof of absence of potential solvent residues can be omitted. The 
solvent free methods are melting methods (e.g. hot melt extrusion) [42; 47; 55], 
co-grinding [56; 57], and sublimation mass transfer [33; 58]. Hot melt extrusion is the most 
applicable despite the limitation to low melting actives whereby degradation can be 
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excluded [29]. Since higher temperatures are applied during the process, this process is not 
suitable for thermolabile actives. Co-grinding is mostly insufficient to convert the complete 
active into the amorphous state. Loading via sublimation mass transfer takes long time and 
leads to low loading levels [59]. 
Between solvent free and solvent using methods stands the loading with supercritical carbon 
dioxide [60-62]. Thereby active is transferred into the pores in a high-pressure chamber [60]. 
After depressurization, the active optimally remains in the loaded silica. Due to the use of 
carbon dioxide, solvent residues can be excluded. However, the cost intensity is above other 
methods.  
For screening of potential silica structures, solvent methods are helpful because of the easy 
change of loading parameters and used active. Especially for thermal labile actives this is the 
preferred option for loading. Problems with possible solvent residues can be prevented by 
using easily vaporizing and dermally compatible solvents. 
Solvent methods are all based on the same principal – the active is dissolved in a suitable 
solvent and mixed with the silica particles. After a certain contact time solvent or remaining 
active solution is removed. Methods can be classified into impregnation [53] and immersion 
methods [63]. The impregnation exploits the pore volume which is filled partly or completely 
by active solution. Solution is added by spraying it onto the silica or by adding it dropwise. 
Spraying is preferred to achieve an even distribution. Afterwards, the solvent is removed by 
use of heat and/or vacuum, whereby the active precipitates in the pores. Crystallization by 
precipitation outside the pores can easily be excluded since the whole added solution is 
soaked into the pores (capillary forces). Adverse are the multiple steps needed to reach a 
certain loading. Number of loading steps depends on pore volume and active concentration 
in the solution.  
For the immersion method, silica is dispersed in the active solution. Removal of the excessive 
active solution or removal of the solvent after a certain time lead to – at least partly – loaded 
silica. Solvent can be removed either by filtration or by evaporation [64]. Filtration leads to 
low loading efficacies, depending on the partitioning of the active between the liquid phase 
and the silica surface/pores. However, they are highly stable [63]. Evaporation increases the 
concentration of the active in the liquid phase and forces the system repeatedly to reach the 
partition equilibrium by precipitation of the active at the silica surface. This can lead to 
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crystallization if the solvent is evaporated too fast. However, high loadings can be reached – 
even if the active is just slightly soluble. The reachable loadings make this method highly 
industrially feasible. Applicable processes for solvent removal are spray drying [65], drying in 
a compartment dryer [51] or solvent evaporation in a rotary evaporator [64]. 
1.5. Pre-requisite for market introduction 
1.5.1. Formulation requirements 
The size of smartPearls can be up to 50 µm. For oral application and tableting this is no 
challenge. It even fulfils the requirement for dermal application of the Ph.Eur. and fits the 
limitation of fine powders (180 µm) [66]. However, in dermal formulations a risk of 
sedimentation exists due to the size and the high density around 2.2 g/mL of silica particles, 
sedimentation must be excluded by selecting an appropriate formulation. Therefore, dermal 
formulations have to fulfil certain viscoelastic requirements prior incorporation of 
smartPearls.  
1.5.2. Demands of an efficient delivery system 
According Jin et al. the amount of smartPearls in dermal formulation is limited by the 
occurrence of sandy feeling [36]. The limitation varies depending on the silica used but is 
mainly at 5%. Depending on the used active and aimed application concentrations of up to 
1% active, an active loading of smartPearls of about 20% is required. Therefore, silica must 
have a sufficient pore volume and surface area to stabilize an adequate amount of active. 
Additionally, the pore diameter should be well above 2 nm to allow not only access of small 
molecules (up to 500 kDa, molecule diameters around 1 nm) but also larger active molecules. 
Even though there is current research about ordered mesoporous silica (cf. Chapter 1.4.1), 
use of non-ordered silica is more feasible because of the price and the regulatory status. Thus, 
development should be based on non-ordered commercially available silica.  
1.5.3. Production requirements 
Several different loading methods (cf. Chapter 1.4.2) are available and certain requirements 
are needed for an industrial feasible production. Thereby, processes are favored which are 
already in use in the pharmaceutical industry since experience and the equipment are already 
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available. The selected process should be as easy and inexpensive as possible without 
compromises in scalability and versatile use.  
For industrial realization predominate the ease of use and more versatile applicability of a 
solvent evaporation process the advantages of solvent free methods. Experience with solvent 
based methods is already available due to previous research in the group of 
Prof. R.H. Müller [36; 67]. Impregnation evaporation (cf. Chapter 1.4.2) is used up to now in 
small scale studies because of the easy change of loading parameters. This process is time 
consuming and highly vulnerable for mistakes. In addition, scaling is difficult. Reproducibility 
is problematic and the process is not industrially feasible. Transfer of the technology to a 
scalable, easy one step process is required for industrial implementation. The immersion 
evaporation (cf. Chapter 1.4.2) process shows all the required advantages. It can be 
performed with a commercial rotary evaporator. Scalability up to several kilograms batch size 




1.6. Aims of the thesis 
Stabilization of amorphous actives by use of porous silica for oral administration is under 
investigation over a number of years. Transferring the technology to dermal administration 
(smartPearls) took place at the end of 2014 as a joint development of the research groups 
R. H. Müller (Freie Universität Berlin) and C. M. Keck (Philipps-Universität Marburg) in co-
operation with the US silica company GRACE. Thus, there is still a need of basic investigations 
to make this technology applicable. The general aim of this thesis was to contribute with basic 
investigations to a better understanding of the system and its industrial implementation. 
The first aim was to summarize the existing knowledge in an overview, that means writing a 
so called “white paper” reviewing the state of the art of the smartPearls technology. The 
performance of smartPearls should be critically discussed and compared to other existing 
dermal delivery technologies, especially the gold standard nanocrystals. 
Application of the silica in fluid/semi-solid dermal formulations instead as a dry powder in a 
tablet or capsule creates a new formulation challenge. The 2-50 µm sized particles undergo 
sedimentation in traditional gels which is not acceptable for a dermal formulation. The second 
aim was therefore to develop physically stable, non-sedimenting formulations based on 
viscoelasticity. 
A variety of silica particles is available, differing in their particle size, pore size, and pore 
volume. Subsequently the third aim was to identify silica particles optimal for loading with 
dermal actives. Ideal silica types should allow a high loading and at the same time preserving 
the amorphous state in the formulation efficiently. To specify ideal silica properties 
avobenzone und rutin were chosen as model actives. At the same time, rutin is an interesting 
antioxidant for anti-pollution strategies being a hot topic in dermopharmacy. 
The fourth aim was to develop a loading process, which is scale-able to industrial scales. To 
enable up-scaling the immersion-evaporation method should be optimized. This method 
should be designed to allow medium sized cosmetic companies to produce products based on 
smartPearls. 
As final aim the acquired knowledge should be used to formulate a challenging cosmetic 
active. Glabridin an highly effective whitening agent with poor solubility was selected for 
investigation. Use of excess amounts to compensate solubility and penetration problems is 
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not possible due to the high costs of glabridin (10,000 USD/kg). SmartPearls might be the 
formulation solution to obtain whitening effects already with small amounts of active. 
Attention should also be given to explore underlying mechanisms, e.g. for factors affecting 
stability of the amorphous state and the technical process of loading on large scale. 
Understanding the mechanisms allows more efficient development of the smartPearls 
technology. 
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General Considerations 
2. smartPearls – Novel physically stable amorphous delivery 
system for poorly soluble dermal actives1 
Abstract 
Dermally applied poorly soluble actives whether in cosmetics or pharmaceuticals show 
insufficient skin penetration. Especially actives being insoluble in both phases of dermal 
vehicles, i.e. water and oil have no or less real effect. An approach to overcome this obstacle 
is the use of amorphous actives instead of the crystalline ones. The higher saturation solubility 
creates an increased concentration gradient between the formulation and skin. Thus, the 
diffusive flux into the skin is improved. However, the amorphous state of actives is highly 
labile, and the durability of such formulations would be too short for a marketable product. 
smartPearls is a novel technology efficiently long-term stabilize the amorphous state. They 
consist of µm sized particles with mesopores (e.g. silica: SYLOID®, AEROPERL®, Neusilin®), in 
which the active can be loaded and preserved in amorphous state. Due to the tightness of the 
pores, not enough space is given for re-crystallization. In this work, the skin penetration of 
poorly soluble actives loaded in smartPearls is compared to the present “gold standards” in 
dermal delivery, e.g. amorphous microparticles, amorphous nanoparticles and nanocrystals. 
The performance was at least similar or even better than the gold standards, explainable by 
the increased saturation solubility of active due to a) amorphous state and b) nanostructure 
inside the µm-sized particles. Sedimentation investigations showed, that the physical 
stabilization of very dense smartPearls in semi-solid vehicles is possible by viscoelastic 
repulsion. Also, the technical, regulatory, and marketing aspects for the use of smartPearls 
technology in products are discussed, e.g. status of excipients used, and advantages of not 
being a nanoparticle, but being as efficient as them. Overall, smartPearls proved to be a 
promising dermal delivery technology for poorly soluble actives with a high market potential.  
                                                        
1  This chapter has been published as: 
Müller, R.H.; Hespeler, D.; Jin, N.; Pyo, S.M.; 2019. smartPearls – Novel physically stable amorphous delivery 





Many poorly soluble actives in cosmetics and pharmaceutics show insufficient skin 
penetration, not reaching the minimum required concentration for real effect. The low passive 
diffusion of active into the skin can be explained by the active’s low solubility, not creating an 
adequate concentration gradient between formulation and skin (Cs-Cskin). Especially actives 
being poorly soluble in water and at the same time in organic solvents, e.g. oils in creams and 
ointments, are highly problematic. Saturation solubilities of so-called poorly soluble actives 
are below 1 mg/mL, including many cosmetically highly interesting antioxidants, e.g. rutin in 
water (75 µg/mL) and resveratrol in water (30 µg/mL) [1; 2]. Also pharmaceutical drugs have 
low solubilities and therewith related penetration problems, e.g. cyclosporine A, 6.6 µg/mL in 
water [3]. Even if those actives are better soluble in the oil phase of dermal vehicles, 
penetration can still be extremely limited since a lipophilic molecule prefers the lipophilic 
surrounding in the oil instead of the lipophilic-hydrophilic skin structure (question of 
partitioning coefficient K). As an old “pharmaceutical rule” for dermal formulations for such 
molecules, the application as aqueous suspension is preferable. 
One strategy to increase the penetration of those actives is the generation of higher 
concentration gradient between formulation and skin by increasing their solubility. 
A meanwhile very old approach is complexation for example with macromolecules, 
e.g. polyethylene glycol or cyclodextrin. The pitfall for such complexes is their potentially high 
binding constant, which even hinders the diffusion of the complexed actives into the skin. In 
case of molecules soluble in organic solvents, water solvent mixtures might be used in the 
dermal formulation. However, after skin application, the organic co-solvent (very often 
ethanol) typically evaporates fast, leading to precipitation of large active crystals on the skin. 
These solid actives are unable to penetrate anymore. Even when using slow evaporating 
co-solvents, e.g. glycerol with a boiling point 290 °C, the active can precipitate in case the 
co-solvent penetrates faster into the skin than the active molecule [4]. This particularly 
happens, when the diffusion coefficient D is considerably higher for the low molecular weight 
co-solvent compared to the high molecular weight active molecule, e.g. glycerol 91 g/mol vs. 
rutin 611 g/mol. 
A highly efficient and well-known strategy to increase the saturation solubility Cs of actives is 
the simple change of their physical state, like creating amorphous particles in the dermal 
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formulation. The amorphous state has generally a higher saturation solubility Cs, precisely a 
so called “supersaturated concentration Css”, compared to the crystalline state. For example, 
solubility of crystalline rutin is 75 µg/mL in water, but 4,000 µg/mL in the amorphous state [2]. 
However, the limitation for the use of amorphous actives is their lack of physical long-term 
stability. Re-crystallization is a statistical event. Thus, physical stability cannot be calculated as 
the chemical stability by using the Arrhenius equation. Due to the non or difficult predictable 
shelf life, amorphous dermal formulations play practically no industrial role. 
An industrially feasible change of particles physical property is the reduction of their size to 
below 1 µm, the so-called nanocrystals. The saturation solubility Cs in a suspension is the 
equilibrium between dissolving molecules (dissolution pressure) and molecules  
re-crystallizing on the surface of crystals (re-crystallization pressure). Below the crystal size of 
about 1 µm, the dissolution pressure increases, and the equilibrium is shifted in favor of 
dissolved molecules, Cs increases. For example, rutin microcrystals have the Cs of 75 µg/mL 
(= thermodynamic equilibrium solubility), but rutin nanocrystals with a size of 727 nm possess 
a Cs of 133 µg/mL [5]. This technology was originally developed from Liversidge and co-
workers to increase the bioavailability of poorly soluble drugs for oral administration 
(company Nanosystem/élan) [6] under the name NanoCrystals. Later on, the nanocrystal 
technology was transferred to the dermal application route by PharmaSol, Germany, under 
the name smartCrystals [7]. Products containing this technology are already on the cosmetic 
market. The first one was introduced in 2007 by Juvena Switzerland and shortly after La Prairie 
followed with the product line Platinum Rare. Besides, various cosmetic actives are 
commercially available as smartCrystal concentrates ready to be admixed into cosmetic 
products (e.g. rutin, hesperidin). The strategy of changing the physical state of actives proved 
to be highly effective for nanocrystals.  
Thus, as next logical development step, both changes (nano-size and amorphous state) were 
combined, to superimpose the solubility enhancing effects of both technologies. According to 
these thoughts, the company BASF generated particles being at the same time in the 
nanodimension and amorphous state. This combination technology developed by Auweter 
and co-workers is called NanoMorph [8] and used in the food sector (e.g. carotenoids for soft 
drinks, LycoVit® [9]), where physical stability criteria is not as strict as in the pharma. In the 
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pharmaceutical sector, this technology was marketed by the company Abbott, but with little 
success, because of the fear of re-crystallization during the shelf life of the final product.  
In summary, the smartest approach for solubility enhancement is the combination of nano-
dimension and amorphous state. However, pre-requisite for industrial use is an effective 
stabilization of the amorphous state in nano-dimension. This was realized by the novel 
smartPearls technology. smartPearls are mesoporous particles made from, e.g. silica or 
polymers and the cosmetic or pharmaceutical active is loaded into the mesopores in the 
amorphous state. The location of active in the pores stabilizes its amorphous state for more 
than 5 years [2]. This article briefly describes the historical development of smartPearls and 
the physics behind the technology, quantifies the penetration enhancement compared to 
already existing technologies, i.e. microsuspensions, nanosuspensions, and outlines the 
production of marketable dermal formulations using viscoelastic gel systems. 
2.2. Historical development 
Identical to nanocrystals, the technology was originally developed for the oral administration 
route with the aim of optimally deliver poorly soluble drugs for an increased bioavailability. In 
1979, Yang et al. improved the dissolution of the drugs prednisolone, digoxin and griseofulvin 
in GI fluids by incorporating them in mesoporous silica particles and many other researchers 
followed working on this principal. A list of the most commonly processed drugs is given in 




Table 1: Overview of the three most frequently incorporated drugs in mesoporous silica. 
 
The first patent application was filed by the company Capsulution Pharma in 
Berlin/Germany [20]. The drugs, e.g. candesartan cilexetil, were loaded into the mesopores of 
silica, e. g. Neusilin® US2. Because an encapsulation was performed in the amorphous state, 
registered trade name was CapsMorph® (PharmaSol/Germany). Re-analysis of about 
30 formulations produced by Capsulution Pharma after more than 3 years of storage showed, 
that all 30 formulations were still in the amorphous state [21]. Meanwhile, this principle is 
also exploited by other companies for oral administration, e.g. Merck Millipore with Parteck® 
SLC; the Belgium company Formac Pharmaceuticals with monodisperse pores [22] and 
Formac Pharmaceuticals in cooperation with W. R. Grace US [23]. In the next development 
step – identical to the transfer of orally used nanocrystals to dermal application – the porous 
particle technology was transferred to the skin by PharmaSol Germany and W. R. Grace 
US [24] with the registered trade name smartPearls. The increased oral bioavailability resulted 
from increased concentration gradient between human digestive system and blood Cs-Cblood. 
drug examples for publications 
Ibuprofen 
NSAID 
2004 Charnay et al. [10] 
2009 Fernandez-Nunez et al. [11] 
2011 Shen et al. [12] 
2012 Vialpando et al. [13] 
2013 Delle Piane et al. [14] 
Naproxen 
NSAID 
2004 Cavallero et al.[15] 
2010 Halamova et al.[16] 
2012 Vialpando et al.[13] 
2013 Guo et al.[17] 
Itraconazole 
antifungal 
2008 Mellaerts et al.[18] 
2011 Kinnari et al.[19] 
2012 Vialpando et al. [13] 
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In principle, the increased concentration gradient should also promote penetration into the 
skin – identical to nanocrystals. 
2.3. Intellectual property aspects 
The transfer from oral to dermal administration route was not implemented because of the 
concern, that re-crystallization should occur in dermal vehicles. In oral tablets and capsules, 
the loaded porous particles are in a dry and solvent-free environment (i.e. a solid-gas 
dispersion), where in contrast dermal vehicles consist of water and/or oil. Even though the 
drugs are poorly soluble, the vehicle still acts as a solvent, promoting the dissolution of drugs. 
When supersaturated state is reached in the vehicle, re-crystallization occurs on the surface 
of amorphous particles, promoting further re-crystallization as an initiator. 
In supersaturated solutions, crystals can also precipitate in the water phase, when heading 
back from the supersaturation solubility Css towards the thermodynamic equilibrium 
saturation solubility Cs. Against these theory-based expectations, no re-crystallization 
occurred in dermal vehicles after smartPearls incorporation. Even in dermal vehicles, the 
amorphous state in smartPearls were physically stabile for up to now 1.5 years. Also, no crystal 
formation was observed in the vehicle itself [25]. These data against the theoretical 
considerations were a) new and b) one of the innovative heights of the patent application [24].  
During the loading process of porous particles, it is unavoidable that small quantities of active 
precipitates on the surface of the porous particles, as shown by Jin et. al. [25]. In the case that 
this layer is very thin, and does not provide enough substance to form crystals, the 
precipitated active remains on the surface in amorphous state. In the case of overloading, the 





Figure 1: From top to bottom: X-ray diffraction patterns of rutin raw drug powder (rutin RDP), physical mixture of 
rutin and SYLOID®, SYLOID® loaded with 33.3% (= overloaded, crystallization of rutin), SYLOID® loaded 
with 32% rutin (= maximum loading) and unloaded SYLOID® (with permission from [25]). 
2.4. Mechanistic considerations 
Precipitation of actives in liquid phases leads in most cases to the formation of crystalline 
particles, µm- or nm-sized (e. g. nanocrystals). Crystals are formed even when the particle size 
is in the range of 20 nm to 50 nm. This principle is applied to produce nanocrystals in the 
bottom-up technology [26]. Thus, only by choosing special precipitation conditions as done in 
the case of NanoMorph [27], amorphous nanoparticles can be generated. However, they 
often still have the tendency to re-crystallize. Porous particles can be loaded by various 
methods [28], e. g. by solvent impregnation [29-31] or solvent free by co-milling [32-34] or by 
supercritical carbon dioxide [30; 35; 36]. In case of the solvent impregnation method, the 
pores are filled with organic solution of the active. Afterwards, the solvent is evaporated and 
the active precipitates. Due to the small size of mesopores (2-50 nm) there is not enough 
space to initiate the crystal formation. This theory is called “space restriction” [18; 34]. Space 
restriction are effective in pores with up to 50 nm in diameters, even though crystals formed 
















in liquid faces without space restriction are 10-20 nm small and would theoretically fit into a 
50 nm pore. In the smartPearls technology no precipitation in amorphous phase was observed 
even for macropores > 50 nm. Data show that the amorphous state in pores is stable for up 
to 3 years in dry powder form [2] and up to 1.5 years in the water phase of dermal vehicles 
(data by now [25], Figure 2 and 3). Investigations were performed by combining X-ray 
diffraction and differential scanning calorimetry (DSC). Based on this data, stable dermal 
formulations are feasible as products for the cosmetic and pharmaceutic market. 
 
Figure 2: From top to bottom: X-ray diffraction patterns of tadalafil raw drug powder (RDP), tadalafil loaded 
Neusilin® US2 (after 3 years of storage) and unloaded Neusilin® US2. No crystallinity peaks were 
detected, thus tadalafil was efficiently preserved in amorphous state (after Grabo et. al. [37]). 
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Figure 3: From top to bottom: X-ray diffraction patterns of rutin raw drug powder (RDP), physical mixture of rutin 
RDP and SYLOID®, amorphous rutin loaded in SYLOID® (rutin smartPearls, after 1.5 years of storage), 
rutin smartPearls incorporate in hydrogel (after 1.5 years of storage) and hydrogel itself. No crystallinity 
peaks were detected for smartPearls, whether as dry powder or in hydrogel, proving the effective 
preservation of amorphous state (with permission from Jin et. al. [25]). 
2.5. Porous particle materials for smartPearls: technical, regulatory & 
marketing aspects 
2.5.1. Technical aspects 
Basically, any porous material can be used for producing active loaded smartPearls, inorganic 
but also organic materials either natural or synthetic. From the technical side, amorphization 
of actives can be already achieved by the interaction of active molecules with carrier surfaces. 
With Increasing interactions between active molecule and carrier surface, also the likelihood 
of active amorphization increases [14]. Creating amorphous actives via this principle is thus 
limited to the specific surface area of the carrier. However, in addition to this surface bonded 
amorphous fraction of active, a large part of active can be amorphized via loading into the 
mesopores of the carrier [38; 39]. This can be explained by the fact that a certain space is 
















needed for the re-crystallization process, which is not given in the mesopores (diameter sizes 
of 2-50 nm). Crucial for this stabilization principle is the selection of the correct pore size in 
relation to the molecular weight of active. Amorphous state is preserved if the ratio of pore 
size to molecule size is smaller than 12 [40]. For a high amount of amorphized active, the 
carrier should possess a sufficiently high pore volume, preferentially in the range of 1.0 to 
1.7 mL/g. Till now, around 1.7 mL/g is the highest pore volume commercially available, 
e.g. SYLOID® and corresponds to a maximum theoretical loading of 75% (w/w) by assuming an 
active density of 2.0 g/mL. 
By using ordered silica, the critical carrier parameters, in particular the specific surface and 
number of surface silanol groups, can be individually adapted to the needs, i.e. the structure 
of active molecule. However, as they are tailor made, the prize is in most cases at least  
10 times higher than for non-ordered silica (~1500 €/kg for ordered silica and ~150 €/kg for 
non-ordered silica). In addition, the majority of ordered silica have not yet been approved as 
pharmaceutical excipients, why the non-ordered silica are still preferred for product 
development. Non-ordered silica have a broader pore size distribution as the ordered silica, 
but long-term stabilization of amorphous state is feasible, and stabilities of even up to 7 years 
are reported. For the selection of a suited non-ordered silica, a safety margin of 5% on the 
upper limit of the pore diameter is recommended. The large number of non-ordered silica on 
the marked possessing different properties, should allow to find a suitable one for many 
various actives. 
Further to these properties, the carrier should have particle sizes preferentially about 1-5 µm 
to minimize sedimentation effect in dermal formulations. Both viscosity and rheological 
properties of dermal vehicle finally determine the maximum possible particle size. A sandy 
feeling on the skin does not even occur with particle sizes of about 50 µm [25], thus can be 
problem-free used in dermal formulations. A sandy feeling on the skin does not even occur 
with particle sizes of about 50 µm [25], thus can be problem-free used in dermal formulations.  
2.5.2. Regulatory aspects 
To be used in market products, the materials should be non-toxic, well tolerated by the skin 
and most important, are regulatory accepted. This is the case for porous silica particles but 
also other inorganic materials, e. g. calcium phosphate. Looking farsighted in the future, 
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materials should be avoided which are still regulatorily accepted at present but might lose this 
acceptance in the future. Examples are particles containing aluminum ions being presently 
heavily under discussion in deodorants [41]. Silica particles used preferentially in dermal 
formulations are various SYLOID® silica particles from W. R. Grace US and AEROPERL® from 
Evonik. Table 2 provides an overview about their most important features. 
Table 2: Overview of silica particles and their relevant properties for the use as smartPearls in dermal 
formulations. 
















5-6 44-177 300 1.2 
AEROPERL® 300 
Pharma 
Evonic Industries AG, 
Germany 
2-20 30-40 300 1.6 
SYLOID® SP53D-
11920 
Grace GmbH & Co. 
KG, Germany 
6 12 550 0.9 
 
2.5.3. Marketing aspects 
The marketing should meet the expectations of the customers. Important is to know, that 
consumers expectations are different for cosmetics and pharmaceutics even though both are 
dermally applied. In dermal pharmaceutics, the patients are willing to accept products with 
unpleasant application properties (application feeling, smell, appearance) or critical excipients 
as long as the therapy of disease is effective. However, in cosmetics the consumer expects 
appealing product properties (pleasant application feeling, pleasant smell). Furthermore, 
consumers expect that modern products are for example natural or organic and not synthetic, 
environment-friendly and if possible, comply with ECOSERT (one of the world’s biggest organic 
certification organization for organic products, also cosmetics, according to ISO 17065). This 
excludes synthetic polymers, especially ones which are not biodegradable. Based on 
ecological expectations, particles from natural materials should be preferred, 
i.e. silica (Table 2). 
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Meanwhile there is an increasing reluctance of the public towards “nano”, promoted by 
newspaper articles how dangerous “nano” is. Nano is still fully accepted in pharma, especially 
if “nano”-pharmaceutics cures your cancer or solves your atopic dermatitis or psoriasis 
problem. “Nano” is also still accepted in cosmetics, since people accept a lot for their beauty. 
But in food sector, it is completely different. Like GMO (gen modified organisms), most 
consumers do not want “nano” in their food products. Cosmetic companies try to meet the 
“anti-nano” trend by developing new products being nano-free, to avoid the INCI declaration 
of nano on product labels. 
Based on this, smartPearls are no nanoparticles according to the EU regulation 
((EC) No 1223/2009). They are clearly in the µm range (EU cosmetic definition of 
nanoparticles: more than 50 % of particles need to be smaller than 100 nm after number 
distribution). Also, according to other non-cosmetic EU regulations (2011/696/EU) the silica 
particles are no “nanomaterial”, since they are dissolvable particles, even though they are low 
soluble. Nowadays, marketing does less emphasize what is in a product, but even more what 
is not in the product, i.e. “free of ...”. Obviously, the consumer is meanwhile focused on this – 
even when the advertising is completely ridiculous. For example, advertising "cholesterol-
free" in products which can absolutely not contain any cholesterol at all being. To meet such 
consumer expectations world-wide, smartPearls can be advertised “nano-free, synthetic-free 
etc.”, and in addition with positive features such as “natural, eco-friendly etc.”. 
2.6. smartPearls on skin – penetration performance 
A pre-requisite for a successful market entry is the presence of a clear advantage whether in 
terms of technology, costs, or marketing. One marketing advantage can be, that a product has 
a “selling story” – despite being not superior compared to other marketed products. A cost 
advantage can be a development of a product performing identically compared to already 
existing products but being less costly in production or in feed material. A technical advantage 
can be that the products performs better compared to already existing products. In case of 
smartPearls this would be the increased skin penetration. 
The present gold standard for improved skin penetration are nanocrystals. Another competing 
technology in skin penetration is the use of amorphous actives, ignoring the hurdle of limited 
physical stability for marketable products. To assess the performance and value of the delivery 
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system, the smartPearls should be therefore compared with nanocrystals and amorphous 
actives (µm-sized). Even more challenging would be if smartPearls would be compared to 
nanoparticles being at the same time amorphous (amorphous nanoparticles), since the 
solubility enhancing effects of nanosize and amorphous superimpose. 
The ideal compound for such a study is cyclosporine A, having poor skin penetration and being 
available as relatively stable amorphous powder. Thus, for the study 3 formulations were 
prepared with cyclosporine A [25]: 
- amorphous µm-crystal suspension gel 
- amorphous nanoparticles (milled by high pressure homogenization) 
- smartPearls loaded with amorphous cyclosporine A 
Penetration was studied ex-vivo on porcine ear skin by tape stripping [42; 43], being a well-
established method to differentiate various dermal formulations regarding both total amount 
of penetrated active and penetration depth. Freshly isolated porcine ears were obtained from 
local slaughterer and used on the very same day for penetration studies. Before usage, the 
integrity of the skin was tested by measuring its transdermal water loss. Only then defined 
amount of formulations were applied on defined area of porcine ear skin and removed after 
20 minutes of application time. The treated skin was removed layer by layer using successively 
30 adhesive tapes. As special challenge, 5% cyclosporine A were incorporated into the 
suspension gel and the amorphous nanoparticle gel, respectively, but only 1% in the 
smartPearls gel.  
The penetration from the amorphous µm-crystal suspension gel is below the other 
2 formulations and the smartPearls formulation is clearly superior, especially in the deeper 
skin layers (Figure 4). For simpler comparison, the penetrated amount in various tapes 
(µg/tape) are normalized by dividing them by the applied total concentration in the dermal 
formulation (i.e. µg per tape/%). Based on these results, the smartPearls are a promising 
alternative to the amorphous nanoparticles and nanocrystals, showing a better performance 
and having the advantage of not being nano, independent from definition used (EU regulation 
< 100 nm or pharmaceutical regulation < 1,000 nm). How can the superiority of smartPearls 
be explained, even being better than amorphous cyclosporine A particles? This is based on 
the fact that the active is in amorphous state and dispersed in the structure of the porous 
particles. Since the pores are between 2-50 
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simultaneously the advantage of being nanosized and amorphous. Since the size in the pores 
are restricted to a maximum 50 nm, they are even finer dispersed than the amorphous 
nanoparticles, leading to higher saturation solubility and thus improved penetration. Also, 
with regards to cost advantages, the smartPearls are superior, since a higher penetrated 
amount was achieved with only one fifth of the concentration used in the nanoparticle 
formulation. Meaning, that for same effectiveness less amount of active is needed. Especially 
in cases of expensive actives, a clear cost advantage is given, e.g. cosmetic antioxidant 
glabridin (about 20,000 USD/kg). smartPearls were also compared to other nanocrystals of, 
e.g. rutin [25] and hesperidin [25]. In all cases, the smartPearls showed a superior penetration.  
 
Figure 4: Penetration profiles of cyclosporine A formulations from top to bottom: amorphous cyclosporine A 
smartPearls in hydrogel (only 1% cyclosporine A), amorphous cyclosporine A nanoparticles in hydrogel 
(5% cyclosporine A) and crystalline cyclosporine A raw drug powder (5 % cyclosporine A). Data were 
displayed normalized by dividing the penetrated amount per tape by the cyclosporine A concentration in 
formulation (with permission from [25]). 
2.7. Final market formulations 
The final market formulations will be typically gels, o/w creams or lotions, where the 




i.e. incorporation into water-free ointments. The particle size needs to be below 50 µm to 
avoid a sandy feeling on skin [24]. Another effect related to size is the potential sedimentation. 
According to Stokes' law sedimentation is a function of size d, particle density σ and viscosity 
η of the dispersion medium. The density of dry, air filled porous silica is very low (σ << 1 g/mL), 
but increases strongly after active loading (σ average of actives around 2 g/mL) and water 
uptake from the dermal vehicle. Based on this, the size should be preferentially even below 
5 µm. However, also distinctly larger particle sizes can be used when incorporated into a 
viscoelastic vehicle. Viscoelastic systems are already well known from food products, 
e.g. salad dressing with non-sedimenting herbs, even when they are resting for years 
(Figure 5, middle).  
In a purely viscous system, sedimentation at a given viscosity is a function of size and particle 
density, being non-existent or very slow for small sized particles with low density (Figure 5, 
left). In a viscoelastic system a rebound effect occurs when a particle is sedimenting. Like 
falling on a spring, the particle is drawn back to its initial position. The related size for non-
sedimenting particles depends on the yield force Fy of the system. If Fy is not exceeded, the 
particles will not sediment, and a stable, non-sedimenting particle dispersion can be obtained 
(Figure 5, right). 
 
Figure 5: Normalized sedimentation velocity per day (z-axis: µm/day) in normal viscous systems as a function of 
particle size (y-axis: µm) and density (x-axis: g/mL) for herbs incorporated in an 1% HPC gel (left). A clear 
sedimentation of herbs is visible. In contrast, herbs stayed homogenously distributed in viscoelastic salad 
dressing (middle), as well as the 50 µm smartPearls in viscoelastic hydrogel (right). The viscoelastic 
stabilization takes place, when the rebound force (Fy) of the elastic gel exceeds the weight force (Fw) of 
the particles (Fy>Fw). 
To assess the difference in suspension stabilization, unloaded smartPearls (SYLOID®) were 
incorporated into a classical viscous hydroxypropyl cellulose gel (HPC, 5%), in a viscoelastic gel 
FW =  weight force
( = f (density, size) )
FY =  elastic 
 stabilization
( = f (yield point) )
particle
stable system: FY  > FW
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obtained by filtration from a viscoelastic salad dressing (KSD) and a self-made, 
pharmaceutically defined viscoelastic gel using ι-carrageenan at 0.35%. To challenge the 
systems, very large sized SYLOID® particles with mean diameters of 150 µm were used. Freshly 
produced gels with SYLOID® were stored in photometric cuvettes and the occurrence or 
absence of sedimentation was investigated by macroscopic observation and photometric 
measurements at a wavelength of 500 nm. In addition, rheological properties of the gels were 
characterized by both shear stress sweep and frequency sweep analysis. Already 1 day after, 
the particles sedimented in the classical viscous HPC gel formulation, with a clear supernatant 
phase being formed (Figure 6, left). In contrast, no sedimentation was visible in both 
viscoelastic gels, salad dressing and ι-carrageenan gel. Also, the photometric value stayed 
constant during storage time. 
 
Figure 6: Macroscopic evaluation of hydrogels (viscous HPC gel, viscoelastic salat dressing and ι-carrageenan) 
without (left) or with 150 µm sized SYLOID® particles directly after incorporation (middle) and after 
storage (right). Complete sedimentation was observed already after 1 day of storage for viscous 
HPC gel, where in salad dressing and ι-carrageenan gel no sedimentation was observed even after 
7 days of storage. 
Rheological evaluation revealed a shear thinning flow behavior for the HPC gel (Figure 7, left). 
For the viscoelastic pharmaceutical gel, a yield point and an elastic limit was detected 
(Figure 7, right). Depending on the yield point and the elastic limit, respective sized particles 
will show no sedimentation at all, staying in abeyance as clearly visible in the macroscopic 
images (Figure 6). Based on this, the addition of viscoelastic gel formers to the water phase of 
dermal vehicles enables the incorporation of relatively large porous particles. Thus, the 




Figure 7: Rheological graphs of HPC and ι-carrageenan gel measured with a 1° cone-plate for  
300 s at a rotation shear stress increasing from 0-100 Pa. A: shear velocity D (y-axis) versus shear stress 
τ (x-axis) is plotted, showing a stronger shear thinning behavior and an elastic limit of 0.01 Pa for the 
ι-carrageenan gel. B: shear viscosity η (y-axis) versus shear stress τ  
(x-axis) is plotted, showing almost similar viscosities for both gels in the linear viscoelastic region. For 
ι-carrageenan gel a yield point at 1 Pa is clearly visible. 
2.8. Conclusions & Perspectives 
The smartPearls technology is at least similar effective as amorphous actives, amorphous 
nanoparticles, and nanocrystals (crystalline nanoparticles). In contrast to amorphous actives, 
the amorphous state in the smartPearls is long-term preserved, and in contrast to amorphous 
nanoparticles and nanocrystals, the smartPearls are not “nano”, meeting the upcoming 
expectations of customers of nano-free products. Based on this, the smartPearls technology 
is a promising delivery system for dermal products, being highly efficient and providing the 
opportunity of market differentiation against competitors. In addition, the excipients are 
regulatorily accepted, commercially available for dermal application (e.g. SYLOID® products 
from W. R. Grace US, AEROPERL® from Evonik, etc.), and provide features such as non-
synthetic and natural. Also, smartPearls is an exclusive technology in the relevant markets, 
not only providing many aspects for market differentiation but also showing superior 
performance. 
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Results and Discussion 
3. smartPearls for dermal bioavailability enhancement – Long-term 
stabilization of suspensions by viscoelasticity2 
Abstract 
smartPearls are a novel dermal delivery system based on mesoporous (pores 2-50 nm) 
particles, developed in 2014. Their pores can be loaded with active which is long-term 
stabilized in its amorphous state. The increased saturation solubility by the amorphous state 
leads to an increased dermal bioavailability of poorly soluble actives. To avoid sedimentation 
of the porous particles (3-50 µm) in dermal formulations, viscoelastic gels were developed 
using i-carrageenan, polyacrylate and the viscoelastic Kühne salad dressing as a reference 
from food industry. Silica particles (company Grace/US, 50 and 150 µm) were loaded into the 
gels and long-term stability was assessed by a VIS sedimentation test. Furthermore, the gels 
were characterized by analytical centrifugation (LUMiSizer®) to assess the critical rpm/g 
values, allowing to order them after their absolute viscoelastic stabilizing ability. 
Characterization was complemented by rotation rheology, amplitude sweep, and a frequency 
sweep analysis for the determination of elastic and viscous moduli G´ and G´´ at varying 
conditions. Based on the throughout characterization, polymers can be selected to sufficiently 
stabilize dermal formulations even with large sized smartPearls – the prerequisite for using 
this delivery system in dermal products. 
 
  
                                                        
2  This chapter has been published as: 
Hespeler, D.; Knoth, D.; Keck, C.M.; Müller, R.H.; Pyo, S.M.; 2019. smartPearls® for dermal bioavailability 
enhancement – Long-term stabilization of suspensions by viscoelasticity. International Journal of 





One approach to increase the bioavailability of poorly soluble actives is their transfer from 
crystalline into amorphous state. Amorphous actives possess a higher saturation 
solubility Cs [1; 2], thus an increased concentration gradient Cs-Ca between donor and 
acceptor compartment, leading to an increased diffusive flux [3]. However, the problem is the 
limited physical stability of amorphous state [4-6], having the tendency to re-crystallize during 
the shelf life of a product. 
In 2009 the German company Capsulution Pharma from Berlin developed the CapsMorph 
technology for oral administration [7; 8]. Drugs are kept in the amorphous state by loading 
them into the mesopores (2-50 nm diameter) of porous materials, e.g. the silicate NEUSILIN® 
US2. Loading was performed by e.g. the solvent impregnation method [9; 10], where drug 
solidifies in the amorphous state after evaporating the solvent. The space restriction in the 
pores effectively hinders crystal formation and also re-crystallization during storage for more 
than 6 years [11]. Beside the space restriction, also physical interactions between the active 
and the matrix are discussed as influencing factors [12; 13]. With regards to regulatory 
aspects, the mesoporous silica particles have a high regulatory acceptance [14], being 
approved as “natural” e.g. after ECOCERT standards. 
As next step, the technology was transferred from the oral administration route to dermal 
application [15; 16]. In a tablet or capsule, the porous particles are in the dry and solvent-free 
state. Being in the water phase of a dermal formulation, the amorphous drug is in contact with 
a liquid. Water is a poor solvent, but still a solvent and therefore a triggered re-crystallization 
was expected. Surprisingly and against the theoretical expectation, the actives in the pores 
remained stable in the amorphous state even in the water phase of dermal formulations [17]. 
After application to the skin, identical to oral delivery, a clear bioavailability enhancement in 
the skin compared to other delivery systems was achieved [17; 18]. Thus, this dermal delivery 
technology – the so called smartPearls – is meanwhile in development with various cosmetic 
and pharma actives to increase their penetration into the skin. 
The technology is in competition with dermal nanocrystals. They are nm-sized crystalline drug 
powders and also provide an increased saturation solubility Cs compared to µm-sized 
crystalline dug powders [19]. However, the increase in Cs by the amorphous state is typically 
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higher than the increase in Cs by nanoization. Thus, the smartPearls have the chance to be the 
successor or at least the alternative technology for poorly soluble drugs or cosmetic actives. 
The nanocrystals have the advantage, that they do not sediment in dermal formulations 
because of their small size. In contrast, the porous smartPearls possess mean sizes between a 
few µm and about 50 µm (being the upper size limit to avoid a sandy feeling on skin), leading 
to sedimentation in “normal” dermal formulations, e.g. conventional creams or gels.  
The aim of this study was to develop formulations preventing the sedimentation. This is the 
prerequisite for the practical realization of smartPearls containing dermal products. Role 
model for this development is the viscoelastic salad dressings from food industry. They can 
stand for months, nonetheless the herbs in the dressing stay nicely dispersed without any 
signs of sedimentation. The principle of viscoelastic stabilization is, that the elastic modulus G' 
surpasses the viscous modulus G''. Further, the flow point of the formulation must exceed the 
sedimentation force of the particles. Various polymers were screened, which yield classical 
viscous systems (cellulose ethers) and polymers which generate viscoelastic gels 
(i-carrageenan, polyacrylate). The rheological properties were investigated, and traditional 
VIS analysis performed to assess the ability of preventing sedimentation (long-term 
stabilization). This test provides typically a yes or no answer but cannot assess the drag forces 
provided by the different viscoelastic gels. Thus, analytical centrifugation was additionally 
applied to place the viscoelastic gel forming polymers in an order of increasing stabilization 
ability. To challenge the system, large silica particles of 50 µm and 150 µm were used. 
3.2. Materials and methods 
Hydroxypropyl cellulose, Klucelä GF Pharma (HPC with a Brookfield viscosity of 400 (2% at 
25°C, 60 rpm) and a molecular weight of 370,000 g/mol was provided from Ashland 
(Schaffhausen, Switzerland). The polyacrylate gelling agent Carbopol® ETD 2020 NF 
(polyacrylate) was provided by Lubrizol (Brussels, Belgium), the i-carrageenan GENUVISCO® 
CG-131 (i-carrageenan) by CP Kelco (Lille Skensved, Denmark). Kühne salad dressing was 
purchased from a local supermarket.  
Silica particles Syloid® XDP 3150 (150 µm) and Syloid® XDP 3050 (50 µm) were provided by 
Grace (Worms, Germany). Microcare® PEHG (liquid blend of ethylhexyl glycerin in 
phenoxyethanol) as preservative was obtained from Thor GmbH (Speyer, Germany). 
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Potassium chloride (KCl) and sodium hydroxide (NaOH) were purchased from Caelo (Hilden, 
Germany). Water was purified with a Millipore System from Merck (Darmstadt, Germany). 
3.2.1. Production of hydrogel bases 
Cellulose ether 
Klucelä GF Pharma (HPC), HPC-M and HEC powder was spread on aqueous 
1% Microcare PEHG solution in an ointment bowl and stored below 8°C for swelling. After a 
swelling time of 24 hours the gel was stirred with a pestle and stored for further 24 hours. The 
gel was produced in a concentration of 5% polymer.  
Dressing 
Kühne salad dressing (dressing) was vacuum filtered with a Whatman® filter type 598 to 
remove the herbs and obtain the gel base. According to the manufacturer specification, the 
dressing contains carrageenan and locust bean gum as gelling agent. Since 
lambda(l)-carrageenan act just as a thickener and kappa-(k)carrageenan forms firm and 
brittle gels, the contained carrageenan is concluded as iota-(i)carrageenan. Further contains 
the dressing spirit vinegar, white wine vinegar, glucose-fructose syrup, salt, spices, sugar, 
sodium acetate, herbs, saccharin, and yeast extract. 
i-carrageenan 
i-carrageenan is a natural product made from red algal species or Irish moss. i-carrageenan 
dispersed in an aqueous 1% Microcare PEHG solution and heating up to 80°C for  
10 minutes lead to a i-carrageenan solution. To form a viscoelastic gel, 10% KCl solution was 
added until the final concentration of either 0.35% (for rheological investigations c.f. section 
2.5) or 0.40% (for all other measurements) was reached [20]. The gel was cooled under 
agitation and replenished to 100 g afterwards. 
Polyacrylate 
Carbopol® ETD 2020 NF (polyacrylate) was dispersed in an aqueous 1% Microcare PEHG 
solution while stirring for at least 15 minutes to ensure a swelling of the gelling agent. 
Afterwards the pH-level was adjusted to 5.5±0.5 with 1 molar sodium hydroxide solution to 
obtain the final gel. Polyacrylate gels were produced at 0.125% for rheological investigations 
(c.f. section 2.5). For all other measurements polyacrylate gels at 0.250% were prepared.  
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3.2.2. Production of silica loaded hydrogels 
smartPearls without drug loading and sizes of 50 and 150 µm were incorporated into all the 
different gels. To avoid a destruction of the incorporated particles a flexible plastic card was 
used instead of a melamine pestle for blending the gel base and the particles in an ointment 
bowl. For VIS investigations, about 30-60 mg smartPearls were incorporated per cuvette filling 
to achieve a transmission below 50%. For the investigation by the analytical centrifuge a 
particle concentration of 1% was favored to avoid possible interactions of the particles and 
influences on the viscosity [21]. 
When incorporating the loaded silica particles into gel, drug will be released into the hydrogel 
– but only to a minor part. Drug dissolves from the pores until a supersaturated solution is 
formed in gel. Because more drug is contained in the pores than it can be dissolved in the gel, 
a major part will remain in the pores. After application to the skin, the drug in the pores acts 
as a depot. When drug from the gel is penetrated into the skin, it will be immediately replaced 
in the gel by new drug dissolving form the pores. To make sure, that drug remains in the pores, 
a sufficiently high drug amount needs to be incorporated into the gel, i.e. multiple of 
supersaturation concentration. 
3.2.3. Sedimentation behavior investigation by VIS analysis and macroscopic 
observation 
Transmission of the loaded smartPearls gels was determined at 500 nm using a PharmaSpec 
UV-1700 (Shimadzu, Japan). The smartPearls loaded gels were filled in 10 mm cuvettes and 
measured directly after preparation. Transmission of the smartPearls gels were normalized 
compared to the pure gel. The transmission approximates to 100% if sedimentation appears. 
The measurements were repeated for stability investigation after one, three, seven and thirty 
days.  
3.2.4. Sedimentation behavior investigation by analytical centrifugation 
Accelerated sedimentation analysis was performed with the LUMiSizer® (LUM GmbH, Berlin, 
Germany). The STEP-technology measures Space and Time related Extinction Profiles, in 
relation to the sedimentation of dispersed particles. Analytical centrifugation was performed 
with 50 and 150 µm smartPearls at low acceleration (250 rpm ≙ 7.8 g) up to high acceleration 
(4000 rpm ≙ 1970 g) to differentiate between viscous and viscoelastic stabilization of the 
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particles, and to assess the critical rpm/g number at which sedimentation occurs in 
viscoelastic systems. The measurement of the transmission was performed at a wavelength 
of 865 nm. 120 profiles were recorded with a five second interval and afterwards 120 profiles 
with a 10 second interval, i.e. a total of 300 scans. For evaluation, all profiles are plotted in 
one overview graph, where the number of scans to be plotted can be selected (e.g. in case of 
300 profiles, each 20th profile can be plotted, corresponding to 15 profiles in total).The 
software displays the time dependence of a single measurement by a change of the color from 
red (first measurement) to green (last measurement). 
3.2.5. Rheological behavior of unloaded and silica loaded hydrogels 
All rheological measurements were performed at a RheoStress RS 100 (Haake, Karlsruhe, 
Germany) with a 60 mm, 1° cone plate geometry and a gap of 1000 µm at 25±1°C. A sample 
amount of 4 mL was filled with a syringe between cone and plate. Shear stress controlled 
rotation rheology, shear stress amplitude sweep rheology and shear stress frequency sweep 
rheology were measured. The measurement routine started with a low shear rate (5 s-1) for 
two minutes to stress all samples similar before measurement. Followed by five minutes’ rest 
time to rebuild the gel matrix. First measurement was the shear stress controlled rotation 
rheology with a shear stress ramp from 0 to 100 Pa, which stopped at 100 Pa or a rotation 
speed of 1000 rpm. Viscous behavior was evaluated from the measured shear rate related to 
the applied shear stress. After a second time of rest for five minutes the shear stress (t) 
amplitude sweep rheology was performed at an angular frequency (w) of 6.28 rad/s (1 Hz) 
from 0 to 100 Pa. The linear viscoelastic area and the flow point were determined based on 
the amplitude sweep test. Afterwards shear stress frequency sweep tests at frequencies w 
from 0.01 up to 100 rad/s were performed at a constant shear stress of 0.2 Pa  
(i-carrageenan gel, polyacrylate gel and dressing) or 0.5 Pa (HPC) which was in the linear 
viscoelastic area, determined from the amplitude sweep analysis. The frequency sweep 
analysis enabled the evaluation of the viscoelastic behavior of gels at low shear stress and 
frequencies, to predict the viscoelastic behavior in the rest state, which is fundamental for the 
interpretation of physical stabilization effects on smartPearls. 
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3.3. Results and discussion 
3.3.1. Light microscopy 
Incorporation of particles into a gel can lead to particle agglomeration or aggregation, e.g. by 
polymer bridging or reduced electrostatic stabilization. Reduction in electrostatic stabilization 
can be caused by particle coating with uncharged polymers (cellulose ethers), or by 
electrolytes being present in a gel (e.g. high concentrations in the i-carrageenan and the 
polyacrylate gels). A simple and efficient tool to assess the even distribution of particles is the 
light microscopy analysis, preferably by low magnifications to screen larger areas for 
aggregates. Light microscopy was preferred to the particle size analysis by laser diffraction 
(LD), since the dilution procedure of the gel being required for performing LD measurements 
might change the dispersion state of the particles. 
Light microscopy images were taken showing the even distribution of the silica particles in all 
gels, exemplarily the cellulose ether HPC, i-carrageenan and polyacrylate gels are shown in 





Figure 1: Light microscopy images of silica (50 µm) in gels, prepared with HPC, i-carrageenan, polyacrylate and 
salad dressing as reference at 100-fold magnification (scale bar: 500 µm). 
3.3.2. Sedimentation behavior investigation by VIS analysis 
Following the Stokes law of sedimentation, the sedimentation velocity is proportional to the 
particle size and the density difference between particle and dispersion medium. Thus, the 
silica particles undergo sedimentation due to their large size (up to 150 µm), in combination 
with a density being distinctly higher than the aqueous gel phase. The unloaded smartPearls 
possess a density of around 1.24 g/mL in water, resulting from the density of silica (2.2 g/mL) 
and the water (1.0 g/mL) in the pores (pore volume 1.8 mL/g). smartPearls loaded with active 
pharmaceutical ingredient (API) can exhibit a density of about 2.0 g/mL, assuming an API 
density of 1.95 g/mL. 
Force F is F=m*g (m – mass, g – gravitational acceleration). The sedimentation force FG 
depends on the density difference of the continuous phase of the formulation rf and the 








𝐹# = %𝜌' − 𝜌)*𝑔	 43𝜋𝑟1 (1) 
For example, the sedimentation force of loaded 50 µm sized smartPearls with a density of 
2.0 g/mL are less than one/tenth of the force of unloaded 150 µm sized particles with a density 
of 1.24 g/mL. Thus the 150 µm particles with pronounced sedimentation were used in this 
study as “challenge test” to identify the gelling agents with the best sedimentation 
prevention. In dermal formulations, only smartPearls with a size of 50 µm or below will be 
relevant since larger particles have a sandy skin feeling [18]. Therefore, if the 150 µm particles 
do not sediment, the practically relevant particles with a size of 50 µm or less will definitely 
not sediment.  
In viscous gels, the sedimentation velocity will only be slowed down by increasing the viscosity 
of the gel phase. Increase of velocity is limited, because good spreadability on the skin must 
remain. In viscoelastic gels, no sedimentation takes place at all if the sedimentation force FG 
is lower than the drag force FD, due to the viscoelastic properties.  
The monitoring of sedimentation behavior was performed by transmission measurements at 
500 nm – a wavelength with high extinction coefficient for particles. Particle concentrations 
in gels were adjusted to obtain a transmission of about 50%, corresponding to about 30 to 
60 mg silica per cuvette. The 50% transmission allowed to monitor both increase due to 
sedimentation and decrease due to potential particle aggregation. In the study no particle 
aggregation took place, as shown by preceding microscopy examination of the gels after 
30 days of storage. Observed increases in the transmission value were thus only due to 
particle sedimentation.  
Measurements to determine the sedimentation behavior only caused by gravity force were 
performed as described in section 2.3. Exemplarily, normalized results for dressing, 
polyacrylate, HPC, and i-carrageenan are shown in Figure 2. No increase in transmission was 
found for the viscoelastic gels, where in contrast, an increase of up to about 95% transmission 
occurred for the viscous HPC gel. The transmission did not reach 100% which was attributed 
to fine silica particles which were form by erosion from the silica particles during the 
incorporation process (mechanical stress).  
In this challenge test with very large silica size of 150 µm, the viscoelastic gels showed one 
month stability. FD was higher than the FG, thus a long-term stability is given, especially when 
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using the practically relevant smaller particles. According to Mezger [22], the shear rate D is 
below 0.01 s-1 in case of sedimentation. Gel bases being able to efficiently inhibit the particle 
sedimentation have to exhibit viscoelastic properties already at this shear rate up to shear 
stresses equivalent to the sedimentation force. 
A concentration of 0.35% i-carrageenan with 0.2% KCl was suitable to stabilize the large silica 
particles, with the advantage of exhibiting liquid like properties, being favorable for good 
spreadability on skin. In contrast, the polyacrylate gel, also sufficient stabilizing properties, 
exhibits a higher viscosity. 
 
Figure 2: Normalized transmission of Syloid® XDP 3150 (150 µm) in commercially available salad dressing, 
5.0% HPC, 0.35% i-carrageenan and 0.25% polyacrylate gel measured after production and 1, 3, 7 and 
30 days storage at room temperature. 
Photos of the cuvettes taken directly after VIS measurements on the day of preparation 
(day 0) and after 7 days of storage are shown exemplarily. Figure 3 shows sedimentation 
occurring in the HPC gel already within 7 days, but a uniform turbidity in the 3 viscoelastic 
formulations, which remained throughout the study (30 days). 
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Figure 3: Photos of gels from 5% HPC gel, commercially available salad dressing, 0.35% i-carrageenan gel and 
0.25% polyacrylate gel without (left, resp.) and with 1% Syloid® XDP 3150 (150 µm) directly after 
production (d0) and after 7 days of storage (d7, right, resp.). Sedimentation only occurred in the HPC 
gel. In the other formulations, the particles remained evenly distributed. 
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3.3.3. Sedimentation behavior of smartPearls in selected gels introduced by 
centrifugal forces 
Theoretical considerations 
The analytical centrifugation provides information about the correlation between: 
a)  applied centrifugal force (controlled via selected rounds per minute (rpm) of 
the centrifuge, 250 rpm ≙	7.8 g; 4000 rpm ≙ 1970 g), and 
b)  the sedimentation behavior (sedimentation yes or no; in case of sedimentation 
about the sedimentation profile and the sedimentation kinetics). 
Important parameter for viscoelastic gels is the centrifugal force g at which sedimentation 
starts, i.e. the sedimentation force FG is larger than the drag force FD of the system. This 
information can be obtained from the sedimentation profiles, being taken by the LUMiSizer® 
(LUM GmbH, Berlin, Germany).  
The homogenously dispersed sample is placed in a cuvette, then sedimentation starts which 
is monitored in the different Spaces of the cuvette as a function of Time, yielding Extinction 
Profiles (so called STEP-technology). In graphical presentation the extinction or alternatively 
the transmission values can be plotted on the y-axis. In this study the transmission was plotted 
on the y-axis, to have increasing values at increasing sedimentation.  
Figure 4 shows the principle set up and sequence of the measurements. The sample filled 
cuvette is placed in the instrument and at time t=0 an extinction (transmission) scan is 
performed over the whole cuvette (Figure 4, upper left). From this scan, an extinction profile 
result (upper right). In the space of the cuvette filled with air, the transmission is 100%, then 
the interface air-liquid (meniscus) is passed, which typically generates a transmission peak. 
After entering the liquid (suspension) phase, a transmission value results depending on the 
turbidity of the suspension. Typically, the particle concentration in the suspension is adjusted 
to about 30-50% transmission for measurement.  
After certain time intervals, the scan is repeated and yielding the profile of the respective 
time-dependent state of sedimentation. In Figure 4 particle sedimentation in a viscous system 
is exemplarily shown, with a clear supernatant, a still turbid medium phase, and a sediment 
which yields almost 0% transmission. In graphs, the extinction (transmission) profile is not 
plotted vertically, but horizontally (Figure 5). In a summarizing graph, all scans taken at 
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different time points are plotted in one graph for better visualization, changing the graph color 
from red (1st measurement) to green (last measurement) (Figure 6). In this study 
240 subsequent scans were performed within one analysis per selected rpm value. Analyses 
were performed at increasing rpm values, i.e. from 250 rpm to 4000 rpm. 
This allows to identify the critical rpm/g value at which sedimentation starts. The higher the 
critical g value is, the higher is the stabilizing ability of the viscoelastic system. The viscoelastic 




Figure 4: Principal setup of analytical centrifuge measurement (upper left) and resulting transmission profile at 
time t=0 of the measurements sequence (upper right). After certain sedimentation times, the scan is 












































Figure 5: Measuring profiles in horizontal plot: At the first measurement (A) the particles are homogenously 
distributed, and the transmission is constant over the whole liquid phase in the cuvette. With increasing 
time of centrifugation, the particles begin to sediment (B), and the upper part of the cuvette is clearing 
up (increase in transmission). The sedimentation process proceeds (C) under a continuing deposition of 
particles at the bottom of the cuvette (sediment). The end of the analysis is indicated by a constant high 
transmission throughout the liquid phase except for the dense sediment at the bottom (D). The sediment 
blocks off most of the incoming light, which leads to a very low transmission close or equal to zero in this 
space of the cuvette. 
For Newtonian liquids (the cellulose derivatives) the sedimentation speed depends on the 
particle size, density of the particles, viscosity of the dispersion medium and the gravitational 
acceleration g (Stokes’s equation). In viscoelastic liquids the sedimentation process is much 
more complex. 
In a viscous Newtonian liquid, the sedimentation velocity v increases linearly with the rotation 
speed, starting at the zero point in the coordinate system. In non-Newtonian liquids, the 
correlation is not linear and strongly depends on the respective gel structure 
(e.g. pseudoplastic, plastic, dilatant). In contrast, viscoelastic systems have a flow/yield point 
above which sedimentation occurs (shear thinning). Below this point, no sedimentation 
occurs, and the suspensions are long-term stable. Above this point, the gel structure is 
changed or even destroyed because of the high g force onto the particles, resulting in higher 
particle weights. The physical stabilization of the particles above this point only rests upon the 
viscosity of the dispersion medium. Aim of this study was to assess if the viscoelastic polymers 
can stabilize under normal storage conditions, and to classify them regarding stabilization at 



















































Analytical centrifugation – data interpretation 
Analytical centrifugation was performed starting with a rotation speed of 200 rpm. After each 
measurement, the speed was increased stepwise up to the maximum possible 4000 rpm. The 
instrument is preferably recommended to be used for suspensions with particle sizes in the 
range 20 nm to about 100 µm. Particle sizes or sedimentation velocities can then precisely be 
calculated from the profiles. This is not the case when analyzing the relatively large particles 
as the silica, because of the increased transmission fluctuation in the profiles (effect of light 
detector dimensions).  
For such particle populations not a quantitative but a qualitative evaluation of the results can 
be made. Larger particles (size close to or larger than the light sensors in the instrument) yield 
extinction/transmission time profiles with higher fluctuations in the values, excluding a 
quantitative analysis. However, the changes in the profiles (moving up of the transmission 
profiles to higher transmission values) can be easily seen in the graphs, being sufficient for 
placing the viscoelastic gels in an order of stabilizing ability. Also, easily detectable is the 
beginning of the sediment formation, occurring when the stabilizing ability is exceeded, and 
sedimentation starts in the viscoelastic systems. 
Transmission profiles are shown for the 3 viscoelastic systems (i-carrageenan gel (Figure 6), 
salad dressing (Figure 7) and polyacrylate gel (Figure 8)) and exemplarily for one selected 
viscous system, the HPC gel (Figure 9). In the Figures 6-9, transmission profiles are plotted to 
allow an easy visual comparison. The last profile shown is the one at which pronounced 
sedimentation in the respective gel occurs (being either 2000 rpm or 4000 rpm). Pronounced 
sedimentation means, that full sedimentation takes place within the first 10 intervals of 
sedimentation profiling (i.e. equal to 10 x 5s = 50 seconds). Table 1 lists the rpm values at 
which rotation speed sedimentation was clearly visible (= critical rpm/g value, e.g. 600 rpm 




Table 1: Overview of critical rpm values, corresponding g numbers and the required rpm for pronounced 
sedimentation (within less than 10 profiles) of the investigated viscoelastic gels and as comparison 
viscous HPC gel. 
gelling agent polymer 
concentration 
critical rpm value corresponding 
g number 
max. rpm for fast 
sedimentation 
i-carrageenan 0.35% 600 47 4000 
salad dressing - 300 12 2000 
polyacrylate 0.25% not reached 
 >4000 
>2100 not reached 
HPC 5.00% viscous system, sedimentation starts at 250 rpm = 8 g 
 
The smartPearls showed no movement in the i-carrageenan gel at 250 rpm. They are 
immobilized by the viscoelastic gel. Hence, a physical stabilization is achieved. The 
corresponding g number is 7.8; meaning that they do not sediment when even about 8 times 
of the gravitational force is applied. Based on this data obtained with 150 µm particles, 
i-carrageenan is a suitable polymer to easily stabilize silica particles of 50 µm. 
At 500 rpm a slight sedimentation could be observed, where at 600 rpm the particles began 
to sediment fast and a complete clearance was nearly achieved. Thus 600 rpm was identified 
as the critical rpm/g values, corresponding to 44 g. At 1000 rpm the sedimentation is 
pronounced. A complete sedimentation would be possible by applying a longer running time 
(i.e. > 3000 s). The fastest acceleration with 4000 rpm showed a complete sedimentation of 
the smartPearls after running just 3 profiles (= 15 s, Figure 6).  
Analytical centrifugation of the salad dressing showed a very slight sedimentation already at 
250 rpm (sedimentation comparable to i-carrageenan gel at 500 rpm). At 500 rpm a visible 
sedimentation occurs, being more pronounced than in the i-carrageenan gel at 500 rpm. Thus, 
this viscoelastic gel has clearly less stabilization ability than i-carrageenan. For the salad 
dressing 300 rpm was identified as critical rpm value, corresponding to 12 g. At 1000 rpm the 
particles fully sedimented within the analysis time, and at 2000 rpm sedimentation was 
completed already after running 2 profiles (= 10 s). In contrast, in the i-carrageenan gel 
4000 rpm was required for such a fast sedimentation – clearly showing its higher stabilizing 
ability. However, the salad dressing can still be used for long-term stabilization, because 1 g 
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at normal storage condition is distinctly away from 8 g, where first signs of sedimentation 
were noted. This salad dressing is on the market with herbs as particles, and stable as a food 
product. Its stabilizing ability has also been confirmed by the VIS measurements in the 
sedimentation study at normal storage conditions.  
 
Figure 6: Sedimentation profiles (transmission vs. position in cell) of 50 µm sized smartPearls incorporated in 
i-carrageenan gel. Very slight sedimentation is recognizable at 500 rpm. For pronounced sedimentation, 
4000 rpm are required (i.e. in this case within 3 profiles ≙ 15 s). 
In summary, based on the analytical centrifugation, the purely viscous gels are not suitable to 
stabilize smartPearls. The viscoelastic gels can be placed in following order of increasing 
stabilization ability: salad dressing, i-carrageenan gel, polyacrylate gel. The i-carrageenan gel 
is relatively low viscous. Thus, it should be preferred to produce dermal formulations with 
good spreading ability on the skin. It is also suitable, when compounds are incorporated into 
the dermal formulations which themselves increase the viscosity (e.g. oil in o/w creams). With 
a stability of up to almost 8 g sedimentation of smartPearls will not occur during processing, 
packaging, or transporting the formulation. The polyacrylate used in the study was relatively 
viscous and suitable for even larger sized silica particles due to its pronounced viscoelasticity. 
In case particles < 50 µm are incorporated, the polyacrylate concentration in the gel can be 
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reduced distinctly below 1% (as used in this study) to make it less viscous, and better 
spreadable. The gel will still have sufficiently high viscoelastic property for long-term 
stabilization. Therefore, both the i-carrageenan and the polyacrylate gels can be used for 
dermal formulations with silica particles. 
 
Figure 7: Sedimentation profiles (transmission vs. position in cell) of 150 µm sized smartPearls incorporated in the 
salad dressing. First very slight sedimentation is recognizable at 250 rpm, where clear sedimentation 
occurs at 500 rpm, and pronounced sedimentation already at just 2000 rpm (i.e. in this case within 
running 2 profiles = 10 s). 
It is remarkable, that the polyacrylate gel showed no signs of sedimentation until the highest 
possible acceleration of 4000 rpm was applied (Figure 8). The change in the top of the cuvette 
can be explained by the particles sedimenting in the upper part. Particles sediment also in the 
lower part of the cuvette but are replaced by particles moving from the upper to the lower 
part. Thus, the transmission stays unchanged in the lower part within the running time of the 
analysis (1,800 s). Critical rpm number of this system is 3600. Based on these profiles, the 
polyacrylate gel is highly suitable for the stabilization of 150 µm smartPearls, and even 
distinctly larger particles can be stabilized when considering the g value 1970. 
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The i-carrageenan gel shows at lower acceleration similar results to the polyacrylate gel at 
4000 rpm. The fast sedimentation of the i-carrageenan gel at higher rotation speeds (2000 or 
4000 rpm) is based on the thinning behavior after the viscoelastic gel overcoming the yield 
point and the viscoelastic structure breaks. 
 
Figure 8: Sedimentation profiles (transmission vs. position in cell) of 50 µm sized smartPearls incorporated in 
polyacrylate gel. No sedimentation was observed for up to 2000 rpm. Slight sedimentation at the upper 
part of the cuvette (cell position 106-118) was visible at a rotation speed of 4000 rpm.  
Figure 9 shows the profiles of the viscous HPC gel as a comparison to the viscoelastic gels. It 
shows that the sedimentation occurs already at 250 rpm and increases distinctly with 
increasing rpm number. Sedimentation is already very pronounced at 2000 rpm. This agrees 
with the theory that purely/dominantly viscous systems show continuously increasing 
sedimentation with increasing g number, according to the sedimentation law by Stokes. 
Complete sedimentation within less than 10 running profiles was not reached at 4000 rpm 
(maximum selectable rpm in the instrument). This can be explained by the relatively high 
viscosity of the 5% HPC gel system. At the end of the analysis time, complete separation was 
reached, as shown by the high transmission. Based on this data, the viscous gel is not suited 
for a long-term stabilization, agreeing with the fast sedimentation observed in the 
VIS sedimentation study. Comparable results were obtained for the other viscous gels (data 
not shown). 
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Figure 9: Sedimentation profiles (transmission vs. position in cell) of 150 µm sized smartPearls incorporated in 
HPC gel. Sedimentation occurred already clearly at 250 rpm. At higher rotation speeds of 1000 and 
2000 rpm the sedimentation is much faster, and the sample is nearly cleared up. Complete sedimentation 
was observed at 4000 rpm, displayed by a constant high transmission over the whole cuvette at the end 
of the analysis time (green lines). The complete sedimentation took distinctly longer compared to the 
viscoelastic gels. 
3.3.4. Rheological behavior of unloaded and smartPearls loaded hydrogels 
Rheological investigations were performed by applying a stress ramp τ up to 1000 Pa, and a 
shear rate D up to 1000 [1/s]. Figure 10 shows the rheograms obtained for the 3 viscoelastic 
gels and the viscous gel HPC. For HPC, the relationship D-τ is practically linear in the log-log 
plot and the flow behavior is almost Newtonian. In contrast, i-carrageenan shows shear 
thinning as seen by the positive deviation to higher D values in the plot. i-carrageenan and 
polyacrylate gels have flow points at about 0.01 Pa and 1 Pa, respectively, and show more 
pronounced shear thinning (steeper increase in D vs. τ), thus showing a plastic flow behavior. 
A relatively high viscosity of the suspension in rested mode, and shear thinning under stress 
conditions is desirable. Then, the suspension is well stabilized during storage but also flows 
well after shaking (application of stress) before dispensing and application on skin. The 
dressing shows less pronounce shear thinning at higher stress. 
250	rpm 1000	rpm
2000	rpm 4000	rpm
105 110 115 120 125 130 105 110 115 120 125 130






























































Figure 10: Rheograms of shear rate D (1/s) in dependency of the shear stress (0‑100 Pa) of the salad dressing, 
0.4% i‑carrageenan, 5% HPC and 0.125% polyacrylate gel. 
Figure 11 (upper) shows the curves obtained by amplitude sweep measurement. G´ and G´´ 
were plotted versus the shear stress τ, where modulus G´ represents the elastic fraction and 
modulus G`` the viscous fraction. Depending on the modulus dominating, the system has more 
elastic or dominantly viscous properties.  
Between 0.1 and 1000 Pa the viscous modulus G´´ is about twice the elastic modulus G´, 
showing that the HPC gel has dominantly viscous property (Figure 11 A, upper curve). This 
agrees with the VIS investigation (sedimentation of the silica within less than 7 days), and the 
results of the analytical centrifuge. The elastic G´ modulus below 0,1 Pa shows high 
fluctuation, thus no reliable interpretation can be given. 
The polyacrylate gel (Figure 11 B, upper curves) shows dominantly elastic properties up to a 
shear stress of around 30 Pa. This confirms the assumption of the VIS investigation of a highly 
viscoelastic gel, being able to stabilize silica particles at least up to 150 µm. On the other hand, 
the spreadability is affected by the viscoelasticity at high shear stress. 




















i-carrageenan shows a more complex relationship (Figure 11 A, lower curves). G´ and G´´ are 
similar up to 1 Pa (linear regions), then up to about 10 Pa G´ is lower with a minimum at about 
5 Pa. Above 10 Pa, G´´ is higher, i.e. the system is dominantly elastic.  
The salad dressing shows a similar complex profile. Only the minimum is shifted to lower stress 
of 1 Pa (Figure 11 B). This might be desirable for a dressing, since the consumer expects a good 
flowability when pouring the dressing from a bottle. At values > 10 Pa, the salad dressing 
possesses identical elasticity as i-carrageenan, having similar G´. 
In summary, the amplitude sweep measurements revealed dominant viscous structure for the 
HPC gel. In contrast, the other polymers showed similar viscous and elastic properties at low 
stress (Pa), and dominantly elastic properties at high shear stress, being equivalent to the 
situation when large particles (= high weight force F) want to sediment in the gel. This property 
is very favorable for incorporating large silica particles of 50 µm or larger. The magnitude of 
the G´ moduli is similar for all viscoelastic gels. Based on these properties all 3 viscoelastic gels 
are suitable for silica containing formulations, and the final selection will depend on other 





Figure 11: A/B: Amplitude sweep measurements from 0.01 up to 100 Pa show the linear viscoelastic area (LVA) for 
the elastic modulus G' (filled symbols) and the viscous modulus G'' (blank symbols) at a frequency of 
6.28 rad/s. C/D: Elastic modulus G' and viscous modulus G'' measured by a frequency sweep test at 
controlled shear stress of w=0.01 up to 100 rad/s. Measurements were conducted for 5% HPC (squares), 
0.35% i-carrageenan (triangles), 0.25% polyacrylate ETD 2000 NF (rhombus) and dressing sample 
(dots). 
The frequency sweep analysis clarifies the influence of the frequency on the measured elastic 
and viscous modulus [22]. In the frequency sweep analysis, except for the HPC gel, all 
measurements were performed at 0.2 Pa, i.e. in the linear viscoelastic area (LVA). Due to non-
linearity of the HPC sample at t=0.2 Pa, a higher value of 0.5 Pa was chosen for the frequency 
sweep analysis. 
Apart from below 0.03 rad/s, the HPC gel showed similar values for both moduli at all applied 
shear stresses of up to 1000 rad/s (Figure 11 C). This means, at low stress (e.g. a suspension 
at resting state) the viscous part dominates with only little contribution of elastic stabilization. 
The G´ value at 0.02 rad/s is below 0.01 Pa. In contrast, the i-carrageenan shows roughly twice 
as high elastic modulus over the whole frequency range (please note logarithmic axis), apart 
from a minimum at about 10 rad/s. This is in agreement with the minimum observed in the 
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amplitude sweep test performed with 6.28 rad/s. These data show nicely the viscoelastic 
stabilization capacity of the i-carrageenan. 
The dressing shows a similar behavior as the i-carrageenan in the frequency sweep analysis 
(Figure 11 D). The shape of the curve is comparable as well as the absolute values measured. 
There is also a minimum for G´ at about 10 rad/s, at which the elastic modulus drops below 
the viscous modulus. This crossover point of the G´ and G´´ curve (= both moduli are similar) 
is at about 6 rad/s, the frequency at which the amplitude sweep analysis was performed. That 
means, that this crossover point is an exceptional situation (at all other frequencies G` is 
higher than G´´). Thus, to obtain an overall picture, it is meaningful to run both the amplitude 
sweep and the frequency sweep analysis.  
The polyacrylate shows a pronounced viscoelastic behavior with almost 10 times higher values 
for the elastic modulus G´ than the viscous modulus G´´ for the entire rage till 60 rad/s 
(Figure 11 D). The crossover point of both moduli is at around 80 rad/s, meaning that the 
stabilization with the polyacrylate gel can be realized for almost the entire observed 
measurement range.  
In summary, the 3 different rheological analyses showed that the elastic contributions were 
at most conditions of shear stress (Pa) and shear frequency (rad/s) dominant, which makes 
the 3 viscoelastic polymers suitable for the stabilization of large silica particles in suspensions. 
The absolute values of G´ and G´´ were much higher for the HPC gel, which is attributed to the 
distinctly higher polymer concentration of 5% compared to e.g. 0.35% in the i-carrageenan 
gel. For the overall stabilization ability, the ratio of G´ and G´´ is important. 
3.4. Conclusion 
As predictable, pure viscous or predominantly viscous systems such as HPC are not able to 
sufficiently stabilize smartPearls suspensions. In contrast, viscoelastic systems are an elegant 
way to avoid sedimentation in dermal formulations, even for 150 µm large particles. 
Stability tests such as the employed sedimentation test can predict long-term stability under 
normal storage conditions, but not in case of special stress which may occur during storage. 
To select a polymer system which has a certain “reserve capacity” for such physical stresses, 
an analytical centrifuge, in this case the LUMiSizer®, proved to be very helpful. The viscoelastic 
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polymers could be placed in increasing order of yield point, representing the point where the 
viscoelastic capacity collapses. Thus, a polymer with desired reserve capacity can be selected. 
The characterization should be completed by rheological investigations to determine the 
elastic modulus G´ and viscous modulus G´´, for the selection of predominantly viscoelastic 
systems. Polymers, such as i-carrageenan, with a low viscosity are preferred to provide a good 
spreadability on the skin. Low viscous systems also have the advantage, that they can be 
“problem-free” added to creams with already high viscosities due to e.g. relatively high 
content of oil droplets. In case that the polymers are relatively viscous (as in this study the 
5% HPC gel and the polyacrylate gel), the problem might be solved by reducing the polymer 
concentration. With this characterization approach, dermal gels and also creams with 
smartPearls can be formulated with sufficient long-term stability. 
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4. Dermal smartPearls – Optimized silica particles for commercial 
products & mechanistic considerations3 
Abstract 
The amorphous state of actives can be long-term stabilized by incorporation into mesoporous 
particles, thus the increase in the saturation solubility by amorphicity can be exploited to 
improve the bioavailability. In this study 5 different silica particles were investigated regarding 
loading capacity and long-term stability of the amorphous form. Five different silica were used 
ranging in pore mean size from 3 to 25 nm, pore volume 0.4 to 1.8 mL/g, and BET surface from 
740 to 320 m2/g. As model active avobenzone was used, because it is a challenging molecule 
by its high crystallisation tendency. To be industrially feasible, a loading capacity of about 50% 
pore volume was investigated. The particles were loaded by an immersion evaporation 
method, being able to be used in industrial production. A theory of the active precipitation in 
the pores was developed based on the Ostwald-Miers range. The 25 nm pore-sized particles 
showed a crystalline fraction directly after loading, the 3 nm and 17 nm pore-sized particles 
after 1 month of storage. Long-term stability of 1 year had the silica with 6 nm and 10 nm pore 
size, thus being ideal for products. By nitrogen sorption studies, primarily filling of the pores 
from bottom to top was identified as loading mechanism. HPLC analysis showed some active 
remaining in the pores due to strong interaction with the pore surface, which needs to be 
considered when developing dermal products. Interestingly, the increase in saturation 
solubility Cs – determined in carrageenan gels – remained also for silica particles showing a 
minor partial crystalline avobenzone fraction. Thus, limited crystallinity does not impair the 
shelf-life and performance of dermal formulations. 
  
                                                        
3  This chapter has been submitted for publication as: 
Hespeler, D.; Pyo, S.M.; Müller, R.H.; 2019. Dermal smartPearls – Optimized silica particles for commercial 





The bioavailability of poorly soluble actives can be increased by converting them from the 
crystalline into the amorphous state, i.e. generating supersaturated solutions Css [1]. This leads 
to an increased concentration gradient across biological membranes, thus to an increased 
diffusional flux and higher concentration in the biological target compartment [2; 3]. 
However, for commercial products with defined shelf life, the instability of the amorphous 
state is a problem [4]. Re-crystallization is a statistical event, and might happen after a few 
days, months, or years of the shelf life. The only solution is to use a reliable technology to 
effectively stabilize the amorphous state [5]. 
One of the technologies is the loading of mesoporous particles (preferentially silica with non-
ordered pores, being already regulatory accepted) with the active, for example the so called 
CapsMorph technology [6; 7] – originally developed for oral administration. The actives are 
loaded inside the pores and stay amorphous because the space restriction inside the 2-50 nm 
pores inhibits crystallization. Thereby the re-crystallisation is thermodynamically completely 
suppressed below a certain pore diameter, or is at least slowed down due to surface effects 
and changes in the nucleation mechanism [8].Physical stability of the amorphous state of 
candesartan cilexetil was proven for up to 4 years [9]. Maleki et al. gives an extensive overview 
of studies using this principal with different silica, loading methods, and actives [10]. 
Most of the silica research development focussed on the oral administration route, dermal 
was neglected [11; 12]. In 2014, as novel approach the technology was transferred from the 
oral administration route to dermal application, the so called smartPearls technology [13; 14]. 
Incorporation of the loaded silica particles into dermal formulations (e.g. gels) created 
supersaturated solution and increased penetration into the skin, being superior even to 
nanocrystals [15] – which can be considered as the dermal gold standard for delivering poorly 
soluble actives. 
The patent application for oral silica (CapsMorph) uses as loading procedure the impregnation 
of particles. The pores are soaked with drug solution, then the solvent from the silica powder 
is evaporated in a rotary evaporator. To achieve a higher loading, multiple soaking and 
evaporation steps are needed – being not an industrially efficient/friendly process. Loading 
can alternatively be performed e.g. with supercritical carbon dioxide [16], but this process 
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requires special equipment and is costly. It is not applicable in an “average” dermal company. 
Thus, in a previous study a one-step loading process was developed, the immersion 
evaporation method [17]. The particles are dispersed in an organic solution of the active, and 
then the solvent is evaporated from the suspension in a rotary evaporator. Volume and 
concentration in the solution are adjusted this way, that in one evaporation step the target 
loading of the silica is achieved. In the development of this method, previously rutin was used 
as model active, being an antioxidant and thus having high relevance for dermal application 
(e.g. intercept radicals formed by IR/blue light in an anti-pollution strategy).  
In this study, avobenzone was used as model active, a UV absorber with high crystallization 
tendency. Thus, it is a suitable, challenging compound to assess the ability of porous silica to 
preserve the amorphous state. Systematically 5 different commercial silica were investigated 
to identify the most suitable silica type for loading varying in particle size (3 to 50 µm), pore 
diameter (3 to 25 nm) and pore volume (0.4 to 1.8 mL/g). Most suitable being defined as 
maintaining the amorphous state the longest time, and at the same time allowing a sufficient 
loading. Many previous studies [18; 19] focus on ordered silica (e.g. to have well defined 
systems). However, they are too expensive for many products. Having the use in cosmetic and 
pharmaceutical products in mind, cost-effective non-ordered silica were used. In addition, 
non-ordered silica particles were selected which are commercially available and are at the 
same time regulatorily accepted, especially for dermal application.  
4.2. Materials and Methods 
4.2.1. Materials 
Silica particles (Table 1) with mesopores of 3, 6, 10, 17 and 25 nm were provided by Grace 
GmbH & Co. KG (Worms, Germany). Avobenzone and ethyl acetate (HPLC grade) were 
purchased from Symrise AG (Holzminden, Germany) and VWR international GmbH 
(Darmstadt, Germany), respectively. Purified water was obtained using a Milli-Q system from 





















Syloid® XDP 3050 25 1.8 320 288 48-66 
Syloid® 244 FP 17 1.6 380 376 2.5-3.7  
Syloid® 72 FP 10 1.2 370 480 4.6-5.8 
Davisil® LC60A 6 0.9 550 600 12 
Syloid® AL-1 FP 3 0.4 740 533 6.5-8.1 
 
4.2.2. smartPearls loading procedure for avobenzone 
All different silica particles were loaded with the immersion evaporation method. Loading of 
48.8% (v/v) of the pore volume was performed. The 48.8% were selected for comparison 
reasons with a loading method used by Jin et. al using the impregnation method with multiple 
loading steps [15]. The resulting theoretical mass fraction in g was calculated by dividing the 
pore volume through the density of the crystalline active. Example (Syloid® 72PF): 1.2 mL/g 
multiplicated by avobenzone density of 1.1 g/mL yielding 1.32 g avobenzone (=100 % pore 
filling). The 48.8% correspond to 0.64 g avobenzone per 1 g silica, i.e. 38.72% avobenzone 
mass fraction. 
For the loading of the pores, a 20% avobenzone ethyl acetate solution was prepared. The 
respective volume of this solution (containing the required amount for loading) was added to 
each type of silica particles. For example, in case of Syloid® XDP 3050 this was 9.13 g of 20% 
avobenzone ethyl acetate solution added to 2 g of silica. The silica was placed in a 250 mL 
round bottom powder flask equipped with baffles, afterwards ethyl acetate solution was 
added. The ethyl acetate was slowly removed from this homogeneous silica dispersion under 
rotation by a rotary evaporator at 40°C and 350 mbar. When a dry powder was obtained, the 
collected solvent in the rotary evaporator was removed, and a past-treatment applied. The 
pressure was slowly reduced over a time period of 10 minutes to 50 mbar to minimize solvent 
residues. In a final step, the flask with the loaded silica was placed into a desiccator at 50 mbar 
for 24 hours. 
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4.2.3. Avobenzone smartPearls characterization and stability determination 
Light microscopy and scanning electron microscopy (SEM) 
Light microscope imaging was performed using a Motic Microscope BA210 (Motic 
Deutschland GmbH, Germany) with a Moticcam camera and the Software Motic Images Plus 
at 100, 400, and 1,000-fold magnification. Scanning electron microscopy (SEM) was performed 
at 10,000-fold magnification using a Zeiss DSM950 (Carl Zeiss AG, Germany). Samples were 
sputter-coated with gold-palladium in an argon atmosphere with 15-20 kV at 0.05 mbar for 
four minutes. 
Crystallinity investigation by DSC (differential scanning calorimetry) 
Differential scanning calorimetry was performed using a DSC 1 (Mettler Toledo GmbH, 
Germany) for the determination of crystalline fraction within the samples. A defined amount 
of about 5 mg (precisely weighted) was sealed in a pierced 40 µl aluminum pan. 
Measurements were conducted with a heating rate of 20 K/min between 25 and 125 °C under 
80 mL/min nitrogen purge. Melting point of avobenzone is 81 °C. 
Confirmation of amorphous state by XRD (X-ray diffraction) 
X-ray diffraction was performed using a Bruker D8 (Bruker Co., USA) to determine the 
amorphous state and potential crystalline fractions of avobenzone in smartPearls. A scan rate 
of 0.02° was used between 2q = 2-60°. The goniometer was equipped with a Cu-anode 
(Ka=0.15406 nm) with a voltage of 40 kV and current of 35 mA. 
Pore and surface specification by nitrogen ad- and desorption 
The samples were outgassed at 30 °C for 24 hours prior the measurement. Nitrogen 
physisorption isotherms with 20 adsorption points between a relative pressure of 0.05-0.99 
and 27 desorption points between 0.99-0.30 were recorded after production with a NOVA 
Quantachrome 4000e (Quantachrome GmbH & Co. KG, Germany) at 77 K (liquid nitrogen). 
Calculations were performed by the provided software NOVAwin 11.0. Pore widths and pore 
volumes were determined after the density functional theory (DFT) and surface analysis after 
the Brunauer-Emmett-Teller (BET) method [20].  
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Avobenzone content determination by HPLC (high performance liquid 
chromatography) 
Avobenzone content was determined by a Kontron 400 System (Kontron Instruments GmbH, 
Germany) equipped with a 20 µl loop and a Nucleosil® 100-5 C18 (250x4 mm) column. Mobile 
phase was methanol:water 85:15 with a flow rate of 0.75 mL/min. UV/VIS detection was 
performed at 355 nm and peak evaluation by the supplied KromaSystem 2000 software. For 
sample preparation a defined amount of about 50 mg were suspended in 25 ml ethyl acetate 
and shaken for 10 minutes. The suspension was centrifugated for 10 minutes at 10,000 rpm. 
An aliquot of the supernatant was diluted by a factor of 200 in mobile phase prior 
determination. 
4.2.4. Determination of the saturation solubility via UV/VIS 
Saturation solubility was determined by a UV/VIS spectrometer PharmaSpec UV-1700 
(Shimadzu, Japan) at room temperature. The raw drug powder and avobenzone smartPearls 
were dispersed in a 0.4% carrageenan gel. The added amount of avobenzone was 10 times 
above the saturation solubility of its raw drug powder. Determination of the saturation 
solubility compared to the avobenzone raw drug powder was conducted one, three and seven 
days after production, and the mean calculated. Concentrations of samples analyzed in the 
spectrometer were adjusted to achieve a spectrum with absorption values between 
0.1 and 2.0. Increase in adsorption due to presence of particles was corrected by evaluation 
of the area under the curve (AUC) instead of the absolute absorption value. Thus, the peak 
area correlates with the concentration. Results obtained with the smartPearls are displayed 
as a multiple of reading measured with avobenzone powder in water (= measure for 
multiplication of saturation solubility).  
4.3. Results and Discussion 
4.3.1. Theoretical consideration for the loading 
The ideally loaded silica particles should contain the amorphous drug in the pores, and as little 
as possible on the particle surface. Based on this, the pore volume is the determining factor 
for the achievable maximum theoretical loading. For example, in case of the particles with 
25 nm pores size (Syloid® XDP 3050), the maximum theoretical loading would be about 
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65% (w/w), calculated considering the crystalline density of the model active avobenzone 
(Table 2). Of course, the pore size has also an influence on the practically achievable loading. 
This influence is rather complex. Larger pores are more easily accessible to the loading fluid, 
smaller pores exhibit stronger capillary forces according to the Kelvin equation. Too small 
pores can hinder the loading (e.g. <2 nm), in case the molecule is relatively large (high 
molecular weight) in relation to the pore. It is an effect comparable to molecular sieving [21]. 
The molecular dimension of avobenzone is about 1.0-1.6 nm, that means in case of the 3 nm 
silica used in this study, it is a pore to molecule ratio of 2-3. Pore volume and pore size 
determine the overall surface of the particle, available for monomolecular adsorption. In some 
cases, the first monolayer adsorbed is more difficult to desorb (stronger interaction forces) 
when the active should be released, leading to some percentage of active remaining in the 
particles [22]. In overall, the key factors are pore volume and pore size, which are 
interconnected by the parameter total surface. A pore volume of 1.8 mL/g with a pore width 
of 25 nm supposing a cylindrical pore relate to an inner surface of 288 m2/g. Taking a certain 
surface roughness into account this value correlates well with the provided BET surface of 




Table 2: Pore volume and resulting maximum mass fraction in case of 100% pore filling and of 48.8% pore filling 
for the different silica. BET surface and mass fraction of loading in case of monolayer adsorption 
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1.8 64.72 47.23 320 1.69 – 3.23 
Syloid® 244 
FP 
1.6 63.32 45.73 380 2.00 – 3.96 
Syloid®  
72 FP 
1.2 56.42 38.72 370 1.95 – 3.85 
Davisil® 
LC60A 
0.9 49.27 32.15 550 2.87 – 5.73 
Syloid®  
AL-1 FP 
0.4 30.15 17.40 740 3.83 – 7.71 
 
To investigate these effects, silica particles were selected ranging in pore volume from 
0.4 mL/g to 1.8 mL/g and having pore sizes from 3 nm to 25 nm (Table 1). Logically the total 
surface is reciprocally proportional to the pore size, i.e. it ranges from 740 m2/g (3 nm) to 
320 m2/g (25 nm). The surface areas cited are the measured BET surfaces, specified by the 
supplier. The calculated theoretical surface values are also listed in a separate column of 
Table 1. 
When selecting the silica particles, preferentially particles were taken which are regulatorily 
accepted as pharmaceutical excipient (all apart from Davisil® LC60A). Due to toxicological 
considerations no aluminum silicates were used, because of the increasing discussion about 
aluminum toxicity in dermal products (e.g. deodorants [24]). Another important factor for 
selection was the particle size. The dermal products should not create any sandy feeling when 
applied onto the skin, that means the particle size should be maximum around 50 µm, as this 
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size cannot be sensed by the skin [13]. The size is also important for the physical stability of 
dermal products. The smaller the size, the less pronounced is sedimentation. Particles with 
decreasing particle size from about 50-65 µm to 3 µm were used in the study. However, 
reducing the sizes only slows down sedimentation velocity, but cannot avoid sedimentation 
in viscous systems. To solve the problem, viscoelastic dermal formulations were developed 
avoiding sedimentation completely even with silica particles of 50-65 µm (Syloid® 
XDP 3050) [25]. 
4.3.2. Avobenzone smartPearls loaded by the immersion evaporation method 
In the immersion evaporation method, the unloaded silica particles are dispersed in the 
solution of active. The solvent is evaporated, the saturation solubility exceeded and the active 
precipitates. From theoretical considerations, precipitation should occur preferentially on the 
surface of the particle, because the rough surface acts as crystallization accelerator. There is 
little probability of crystals forming in the solvent phase. Because the pore surface represents 
more than 99% of the total particle surface, the active will preferentially localize in the pores, 
but some also on the surface. Thus, to achieve a complete loading of 100% of the pores is 
rather difficult without having some amount localizing on the surface. In contrast to the pores 
(e.g. 10 nm), this surface layer has no special restriction in thickness. Thus, exceeding a critical 
threshold of thickness, crystallization occurs. To minimize the risk of such crystallization, in 
this study a theoretical loading of about 50 % of the pore volume was aimed. This correlate to 




Table 3: Calculated loading (mass fraction) according to the used weight fractions (silica and avobenzone 
solution) in the loading process, and the mass fraction determined by HPLC after loading for each silica. 








25 nm 48.0 29.9 1.2 
17 nm 41.9 28.2 4.1 
10 nm 35.1 21.5 3.5 
6 nm 28.9 16.6 4.2 
3 nm 17.5 8.3 2.0 
 
To assess the critical limit of loading (= occurrence of first crystallization), the silica particles 
were loaded, and the physical state of avobenzone determined by DSC and X-ray diffraction. 
Avobenzone has a melting peak of 81 °C, clearly detectable by DSC (Figure 1, upper curve). 
The empty silica particles are amorphous, no peak is detectable, exemplarily shown for the 
6 nm silica. Mixing avobenzone with 6 nm silica (physical mixture), an avobenzone peak is 
detectable. In contrast, all thermograms – apart from the 25 nm – show no detectable peaks. 
The avobenzone peak in the 25 nm silica particles is shifted to a lower temperature due to a 
melting point depression. This can be attributed to partial crystallization in confined spaces of 
a molecule pore ratio between 12 and 20 [26]. In summary from the DSC data, all particles 
apart from the 25 nm ones seem to be able to be loaded with about 50% (v/v) related to their 
respective pore volume. The loaded pore volume percentage is identical for all particles, but 




Figure 1: From upper to lower: Thermograms of avobenzone, silica particles (6 nm), 0.7% physical mixture and 
avobenzone smartPearls with 3, 6, 10, 17 and 25 nm pores, with avobenzone content according to Table 
3. 
To verify the amorphous state, X-ray diffraction (XRD) of the particles, being identified as 
amorphous by DSC, was performed. The X-ray diffractograms show a nice crystalline pattern 
for avobenzone, an amorphous halo for the empty silica particles and a small detectable peak 
in the physical mixture (Figure 2, upper 3 curves). In contrast to the DSC data, also crystallinity 
was detectable in both the 3 nm and the 17 nm particles. The XRD data were collected 4 weeks 
after particle loading. Performing again DSC with the 3 nm and 17 nm particles also revealed 
crystallinity (Figure 3; 3 and 17 nm DSC curves). 
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Figure 2: From top to bottom: XRD diffraction pattern of avobenzone, silica particles (6 nm), physical mixture 
(1.5%) and avobenzone (avo) smartPearls with 3, 6, 10, 17 nm pores (loading according to Table 3) 
4 weeks after production.  
A theoretical loading of 48.8% was tried to be achieved. This corresponds to avobenzone mass 
fractions between 17% and 48% depending on the silicas pore volume determined by weight 
(Table 3). In parallel, avobenzone was extracted for HPLC analysis. The percentages by HPLC 
were all below the calculated loading percentages (e.g. 25 nm particles: 29.9 % obtained by 
HPLC compared to 48% calculated based on the mass fractions used). This is a clear indication, 
that some avobenzone is bound firmly to the silica surface, a phenomenon described 
previously [22; 27].. The incomplete release needs to be considered when developing dermal 
formulations. 
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4.3.3. Loaded avobenzone smartPearls – 1 year long-term stability 
All loaded particles were analyzed again by DSC and XRD during storage (Figure 3 and 
Figure 4). Directly after loading, only the 25 nm particles showed crystallinity by DSC. After 
4 weeks of storage – the 3 nm and 17 nm particles also showed crystallinity (in agreement 
with 4 weeks XRD data). After 1 year of storage, the 6 nm and 10 nm particles showed still no 
peaks, i.e. according to DSC the avobenzone is still amorphous (Figure 3), of course within the 
detection limit of the method (0.7% avobenzone). 
 
Figure 3: DSC thermograms of 3 nm (black), 6 nm (green), 10 nm (blue), 17 nm (red) and 25 nm (violet) 
smartPearls after production and after 4 weeks or one year storage (upper and lower curve, resp.). 
Interestingly, also after 4 weeks, there was a change in the DSC diagram of the 25 nm particles. 
A second peak occurred at 81 °C, approx. the melting point of crystalline avobenzone. The first 
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peak detected directly after production showed only the peak associated to avobenzone 
melting point depression compared to 81 °C. A possible explanation is that the two peaks 
originate from avobenzone differently located. Potential different locations are at the particle 
surface and inside the pores. Thus, delayed crystallization is assumed within very large pores 
or at the surface of the particles. It should be kept in mind, that the specified pore diameter 
is an average, the pores show polydispersity with distinctly larger pores than the 25 nm. In 
these pores’ crystallization should preferentially happen. 
In parallel, the 6 nm and 10 nm particles were also analyzed by XRD. Figure 4 shows the 
diagrams after 4 weeks in comparison to after 1 year. No change occurred, the avobenzone is 
physically stable in the amorphous state. Of course, one needs to consider the detection limit. 
Thus, physical mixtures were prepared with decreasing amounts of avobenzone. By DSC an 
admixture of 0.7% avobenzone was still detectable (Figure 1, 3rd curve from top), by XRD the 
detection limit was 1.5% (Figure 2, 3rd curve from top). 
 
Figure 4: XRD diffraction pattern of physically stable avobenzone smartPearls: with 6 nm (blue) and 10 nm (violet) 
pores after 4 weeks and 1 year storage. 
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4.3.4. Characterization of avobenzone smartPearls by microscopy 
The physically stable particles (6 nm, 10 nm) were analyzed by light microscopy and scanning 
electron microscopy (SEM) to get an impression of their appearance, especially looking at 
potential changes after loading. Exemplarily the images of the 6 nm particles are shown. The 
results were identical for the 10 nm ones. 
Light microscopy shows dark avobenzone particles in the range of about 50 to 150 µm. They 
are crystalline. The unloaded silica particles appear translucent. They are polydisperse with 
sizes from about 10 to 20 µm, the supplier specification of mean size is 12 µm (determined by 
laser diffraction). After loading, the silica particles slightly darkened, which was attributed to 
the avobenzone (Figure 5, upper). 
 
Figure 5: Upper: light microscopy images of avobenzone (left), 6 nm silica (middle) and respective avobenzone 
loaded silica (right), 1,000-fold magnified. Lower: corresponding SEM images 10,000-fold magnified. 
The SEM images show large avobenzone particles, but also small crystals of about 1-2 µm 
adhering to the surface of the large avobenzone crystals. The unloaded silica show a smooth 
surface, with a few imperfections. After loading, the surface appearance did not significantly 
change, supporting that the dominant fraction of avobenzone is localized rather in the pores. 
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4.3.5. Nitrogen ad- and desorption studies 
Nitrogen ad- and desorption is a commonly used method for determination of BET surface, 
pore volume and pore size [28-30]. This method was used to measure the change in 
BET surface, pore width and pore volume of the investigated silica by the loading with 
avobenzone. Data are shown for the physically stable 6 nm and 10 nm particles. The isotherms 
should give more insight into the loading mechanism of the avobenzone. Figure 6 shows the 
isotherms (upper) and the respective calculated pore volume and pore diameter (lower). 
 
Figure 6: Top: Nitrogen ad- and desorption isotherms plotted for standard temperature and pressure (STP) of silica 
and their respective avobenzone loaded smartPearls with 6 nm (A) and 10 nm (B) pores.  
Bottom: Cumulative pore volume (straight lines) and pore volume distribution dV(d) (dashed lines) over 
the pore width for silica and smartPearls with 6 nm (C) and 10 nm (D) pores. 
The ad- and desorption isotherms show a H1 hysteresis [31]. This indicates that no bottle neck 
pores are present. After loading, the adsorbed nitrogen volume decreased clearly, but the 
hysteresis type of the isotherms remained. That means there is no change in the pore form, 
being the same for both, unloaded and loaded silica. Also, a pore blocking can be excluded 
(Figure 6, upper). 
Figure 6 (lower left) shows that the mean pore width of 6 nm silica particles decreased very 
slightly from 5.69 nm to 5.44 nm after loading with avobenzone. The same was observed for 
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the 10 nm particles (decrease from 7.80 nm to 7.12 nm) (Figure 6, lower right). This very slight 
decrease supports that deposition of the avobenzone did not take place mainly by multilayer 
adsorption on the pore surface but by simple filling of the pores. The only very slight reduction 
in pore width indicates a thin layer (mono or bimolecular) of avobenzone on the surface. 
Hempel et al. assume this surface adsorption to be the main stabilizing effect for the 
amorphous phase [32]. In this study, mainly pore filling occurred, thus the space 
restriction/confinement by the small pore diameter is the mechanism for amorphous phase 
stabilization [26; 33]. 
By the loading, the pore volume decreased from 1.06 mL to 0.40 mL (10 nm silica) and from 
0.84 to 0.35 mL (6 nm silica) (Figure 6, lower). Theoretically the volume should decrease by 
about 50 %, the measured decrease was about 58.3 % and 62.3%. A potential explanation is 
the different (lower) density of the amorphous phase compart to crystalline avobenzone. 
From the isotherms, the BET surface was calculated. After loading, the BET surface decreased 
to 68% and 66% for the 10 and 6 nm silica, respectively. The surfaces decreased from 355 to 
113 m2/g and from 412 to 139 m2/g, respectively. Such a pronounced surface reduction can 
only be explained by bottom to top pore filling; thus, the data support the proposed loading 
mechanism. 
4.3.6. Determination of saturation solubility 
The increase of the saturation solubility Cs is the interesting feature of the amorphous state 
in the porous silica particles. To reflect better the application situation in a dermal 
formulation, the loaded particles were incorporated into a carrageenan gel. Carrageenan was 
used because it creates a viscoelastic system avoiding the sedimentation of the particles [25]. 
Compared to the raw drug powder, Cs increased by about a factor of 4 for all different silica 
particles (Figure 7). This indicate that pore volumes, diameters and surface play no role – 
determining for the solubility is only the amorphous state. Several studies focus not on the 
saturation solubility but on the influence of the pore diameter on the release 
properties/dissolution velocity [34; 35]. With increasing pore size (~10 nm) the influence of 
the pore diameter gets less [34]. In comparison, Rikkonen et al. reports a strong dependency 
of the release on the loading level and no significant correlation with the carrier 
properties [36]. However, the focus of this study is on dermal application and the carrier is 
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already incorporated into a dermal formulation. The active is thus already in the 
supersaturated state within the formulation, when it will be applied to the skin. The release 
of the active out of the silica has only the function to replace dissolved molecules in the 
formulation which are penetrated into the skin. The release velocity is no determining factor 
for skin penetration (skin diffusion is limiting factor). Studies showed that the formed 
supersaturated state remains in the dermal formulation. 
 
Figure 7: Mean saturation solubility of avobenzone RDP (raw drug powder), 3, 6, 10, and 17 nm pored avobenzone 
smartPearls. 
Highly interesting is, that also the silica particles with a minor crystalline fraction (3 nm and 
17 nm) had similar increase in solubility, that means, even particles with some crystalline 
fraction present can be used without problems in dermal formulation. Occurrence of a 
crystalline fraction during the shelf life is not limiting dermal products. 




























4.3.7. Mechanistic considerations – loading process 
In the loading procedure, unloaded porous silica are dispersed in a saturated solution of the 
active, in this case avobenzone. In the subsequent step, a supersaturated solution is created 
by evaporation of solvent. The precipitation occurring can be better understood on the basis 
of the Ostwald-Miers diagram, and the Ostwald-Miers range [37; 38]. 
The Ostwald-Miers concentration range is the range in which supersaturation occurs during 
cooling of a solution, without the occurrence of spontaneous nucleation. To a given 
temperature Ts of a solution, a certain saturation solubility Cs is related. A solution with the 
concentration Cx is cooled. When it reaches Ts, Cx is equal to the saturation solubility Cs. In a 
close range below Ts (Ostwald-Miers range), the solution remains in a supersaturated state. 
Precipitation and following crystallization occur only, when it is initiated, e.g. by seed crystals 
or rough surfaces, which promote precipitation (in the case of the silica by their rough 
surface). In the Ostwald-Miers range, the concentration of the solute Cx is above the 
saturation solubility in the temperature range Ts-crit. Further cooling below the critical 
temperature Tcrit leads to such a high energy state of the solution that spontaneous nucleation 
occurs. The precipitation starts (Figure 8, left). Further cooling of the solution leads to 
continuous precipitation, the concentration of the solute reduces and follows curve B 
(Figure 8, left). 
 
Figure 8: Left: Supersaturation and precipitation according to Ostwald-Miers depending on temperature.  
Right: Precipitation on silica surface induced by solvent evaporation (explanation cf. text). 
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Instead of cooling a solution, a supersaturation can be generated by evaporation of the 
solvent as it happens in the loading process of the silica. The volume decrease corresponds to 
the temperature decrease. Without the presence of silica particles, the active would remain 
in solution in the volume range Vs-crit. However, because the rough surface of the silica is 
present, precipitation is initiated (Figure 8, right) within the Ostwald-Miers range, at the 
volume Vi. Due to precipitation, the concentration of the solute reduces until the Cs and the 
volume Vi is reached (= Csi) (Figure 8, right, line B). Further removal of solvent leads to 
repetition of this process, continuing precipitation on the surface. 
Precipitation takes place on the surfaces, the surface of the pores represents the largest 
surface area, thus on the mass balance preferentially precipitation occurs inside the pores. 
With continuing evaporation, the precipitation continues until the solvent has completely 
been evaporated.  
Assuming a 50 µm particle (diameter) with a pore volume of 1.8 mL, and a pore diameter of 
25 nm, the surface area of the particle (outer surface) assuming a sphere is 0.12 m2/g (bulk 
density of 0.42 g/mL and silica density 2.2 g/mL). The total surface area of the particles (outer 
+ inner pore surface) is 320 m2/g, thus the outer surface is less than 1% of the total surface. 
Most of the active precipitated inside the pores is not able to form crystals, thus only the 
active precipitated at the outer surface or in large pores (as discussed for 25 nm silica) is able 
to form crystals if the active layer reaches a certain thickness.  
During the precipitation, formation of separate crystals in the solvent phase has to be avoided. 
Spontaneous nucleation and separate formation of crystals can only occur, when very fast 
removal of the solvent is performed, and the supersaturation curve in the Ostwald-Miers 
diagram is reached. Based on these theoretical considerations, the evaporation should not be 
too fast, precipitation should be initiated by the silica surface in the Ostwald-Miers range. 
4.3.8. Mechanistic considerations – pore volume & occurrence of crystalline 
fraction 
The silica with the 3 nm pores showed already a crystalline fraction shortly after loading. This 
could be explained by the size restriction of the 3 nm pores for molecules with a diameter of 
1.0-1.6 nm. The diameter from avobenzone was derived by the minimum and maximum 
projection radius (calculated by ChemAxon). Due to the hindered access into the pores an 
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increasing number of molecules localizes on the particle surface with continuous solvent 
evaporation in the immersion evaporation method (Figure 9, upper left and middle). When a 
critical threshold of surface layer thickness is exceeded, crystallization on the surface occurs 
(Figure 9, upper right). The pore volume is no critical point, because the anticipated loading 
was below the respective pore volume of all investigated silica particles. 
For the particles with larger pore size, a crystalline fraction was observed directly after loading 
(25 nm), or after 1 month of storage (17 nm). In contrast to the small 3 nm pores, the 
molecules have easy access to these pores. With increasing removal of solvent, more and 
more molecules localize in the pores. In contrast to the small pores there is very little 
adsorption (seen as mass fraction) onto the particle surface (pore surface is 99% of total 
particle surface) (Figure 9, lower left and middle). In case of a large mean pore size (25 nm), 
due to the polydispersity of the pore sizes, very large pores are also present. There is no 
efficient size restriction, the molecules of the unordered amorphous state can re-orientate 
and form crystals. In case of slightly less pore size (17 nm), there is a certain hindrance of the 
smaller pores, delaying the process of re-ordering. It takes more time, and a minor crystalline 
fraction can be observed after 4 weeks of storage (Figure 9, lower right). 
Ideal for a stable amorphous state are the particles with medium pore size of about 6 nm to 
10 nm. They allow sufficient access for the model molecule to the pores (pores to molecule 
size ratio >2). In addition, the pore diameter is sufficiently small for effective space restriction 




Figure 9: Mechanisms of molecule deposition during the immersion evaporation process on silica particles with 
small pores (upper) and relatively large pores (lower). During solvent evaporation, the molecules deposit 
differently inside the pores (hindered vs. easy pore access) and on the surface (pronounced deposition 
vs. slight deposition) for the silica with small and large sized pores, respectively. Detailed explanation 
cf. text, section 4.3.8. 
4.4. Conclusion 
Different silica particles varying in mesopore size, pore volume and surface were investigated. 
To be industrially feasible for products, a loading of about 50% pore volume is desirable which 
should be long-term stable. In summary, very small pores of 3 nm at the lower edge are not 
suitable. They hinder the location of molecules in the pores, and a crystalline fraction occurs. 
Larger pores of 17 nm and 25 nm lead also to crystallization, due to the polydispersity in the 
pore size. The very large pores being present promote crystallization. Thus, pore sizes of 6 nm 













































Based on nitrogen isotherms, the basic mechanism of loading was primarily filling pores from 
bottom to top. Adsorption onto the pore surface takes also place, as proven by the HPLC data. 
No 100% recovery of the loaded avobenzone was possible due to firm binding of molecules to 
the pore surface (being 99% of total surface of the particles). Thus, when developing products, 
excess of drug needs to be used to compensate the non-releasable fraction. 
Highly interesting is, that formation of a small crystalline fraction did not affect the solubility 
increase generated by the amorphous form. Partial crystallinity does not impair the quality of 
the dermal formulation/product. Finally, important is that the loading was performed with a 
method which can be used in industrial production [17]. Combining the loading method with 
the use of the identified optimized silica particles enables commercial products. 
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5. Nanoporous dermal smartPearls – Identification of optimal silica 
types & scale-able production process as pre-requisites for 
marketed products4 
Abstract 
Dermal smartPearls are a dermal delivery system for poorly soluble active agents, consisting 
of nanoporous silica particles loaded with a physically long-term stable amorphous active 
agent in its mesopores (2-50 nm). The amorphous state increases dermal bioavailability. For 
use in marketed products, optimal silica types were identified from commercially available, 
regulatorily accepted silica. In addition, a scale-able production process was used. Loading of 
the particles was performed applying the immersion-evaporation method. The antioxidant 
rutin was used as model active agent, ethanol as unproblematic solvent. Various silica 
particles (Syloid®, Davisil®) differing in particle size (7-50 µm), pore diameter (3-25 nm) and 
pore volume (0.4-1.75 mL/g) were investigated regarding their ease of processing. 
Evaporation from the silica-ethanol suspensions was performed in a rotary evaporator. Best 
flowable powders were obtained with larger sized silica. The maximum amorphous loadings 
achieved were between 10% and 25% (w/w), depending on the silica type. A mechanism of 
loading is proposed. Most suitable regarding processing was the large sized silica 
Syloid® XDP 3050 with 50 µm particle size and largest pore diameter of 25 nm and 18% (w/w) 
maximum loading. Based on a 10% (w/w) loading and the amorphous solubility of the active 
agent, for 100 kg dermal formulation about 500 g loaded particles are required. This 
corresponds to production of 5 kg loaded smartPearls for a formulation batch size of a ton. 
Production of 5 kg (= about 25 L solvent removal) can industrially be realized in a commercial 
50 L rotary evaporator. 
  
                                                        
4  This chapter has been submitted for publication as: 
Hespeler, D.; El Nomeiri, S.; Kaltenbach, J.; Müller, R.H.; 2019. Nanoporous dermal smartPearls – Identification 
of optimal silica types & scale-able production process as pre-requisites for marketed products. Beilstein 




Many interesting active agents in pharma and cosmetics are poorly soluble. Active agents 
poorly soluble in water, but soluble in lipophilic media can easily be formulated as creams or 
gels (e.g. the popular coenzyme Q10). The problems start when the active agents are poorly 
soluble simultaneously in aqueous and lipophilic/organic media. Classical examples are 
antioxidants (e.g. rutin, hesperidin, etc.), presently highly en vogue in cosmetics for anti-
pollution products (the “molecular barrier” against ROS (reactive oxygen species), IR radiation 
and blue light from computers) [1; 2]. For the delivery of such molecules efficient delivery 
systems are the only solution, because applying simple suspensions to the skin normally does 
not provide a sufficient dermal bioavailability. 
Classic delivery systems such as liposomes [3] or solid lipid nanoparticles (SLN) [4; 5] do not 
work, because the active agents do not dissolve in the lipidic phase of these systems. A simple 
but very effective approach is to increase the saturation solubility of these active agents. This 
leads to an increased concentration gradient between formulation and skin Cs-Cskin, and thus 
to an increased diffusional flux into the skin. Moreover, using e.g. complexes with polymers 
or cyclodextrins can be of limited effect, because of insufficient release of the molecules from 
such complexes (too high binding constants) [6; 7]. Additionally, many molecules are not able 
to form such complexes. A highly effective way is the dermal administration of nanocrystals 
(trade name smartCrystals®) [8-10]. They are on the market in commercial dermal cosmetic 
products since 2007 (e.g. hesperidin, la prairie Switzerland) [11; 12]. They can be considered 
as the present “gold standard”. 
The trick with nanocrystal is that transfer of the material from the µm-dimension into the 
nano-dimension changes distinctly physicochemical properties, e.g. the saturation solubility 
distinctly increases [13]. In general, amorphous materials have an even higher Cs than 
nanocrystalline materials [14]. Thus, it would be most effective to use active agents in the 
amorphous state. 
However, the amorphous state is physically unstable. Because of the high free energy the 
amorphous phase tends to re-crystallize [15], especially in presence of liquids [16]. This 
hindered the broad use of amorphous active agents in dermal formulations. The company 
Capsulution (Berlin) incorporated active agents in the amorphous state inside the pores of 
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silica particles with mesopores (2-50 nm) [17], technology CapsMorph for oral administration 
[18]. By this, the amorphous state could be stabilized over years [19]. Porous silica particles 
are commercially available e.g. from Grace, Merck Millipore and Formac [20]. They are 
nanoporous materials, because their pore diameter is in the nanometer dimension (>1 nm 
and below 1,000 nm) [21]. The silica used had so called "mesopores", i.e. nanopores in the 
range 2-50 nm. In 2006 this delivery technology was transferred from the oral to the dermal 
administration route [22], technology called smartPearls [23]. The name was changed to 
smartPearls to clearly differentiate them from silica used for oral administration. 
SmartCrystals are in products on the cosmetic market, because industrial large scale 
production is possible and there is an industrial supplier (Dr. Rimpler GmbH, Germany) for 
manufacturers of cosmetics. SmartCrystals are crystals in the nanometer dimension, typically 
200-400 nm, which can be produced on large scale by bead milling or high pressure 
homogenization. Skin penetration studies showed that the smartPearls were superior to the 
nanocrystals [8; 24; 25]. However, the market introduction in final cosmetic products is 
blocked due to the lack of an industrial supplier of active agent-loaded smartPearls. To 
establish an industrial supply, an industrially feasible production method is required. 
Silica particles can be loaded e.g. by co-milling [26; 27], but a large part of the active agents 
stays outside the pores. Loading can be performed by supercritical carbon dioxide [28], but it 
is expensive. Loading is possible by the impregnation-evaporation method [29], but this is less 
suitable in large scale. In this study, the immersion-evaporation method [30] was applied and 
systematically investigated to define large scale production parameters for an industry 
friendly one step production process. Rutin was used as model active agent, because it has 
high application potential in cosmetic products, but is also of use in dermal pharmaceutical 
products [31]. A mechanism of loading in this industrial process is proposed. In addition, 
concentrations of smartPearls in final dermal products are suggested based on achieved 
loadings and on solubility data. This could be a guideline for manufacturers of dermal 
products. Different silica types were investigated (particle size, pore diameter, pore volume) 
to identify the particles which are most easily processable. 
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5.2. Materials and Methods 
5.2.1. Materials 
Rutin with a purity of 95% was purchased from Denk Ingredients (Munich, Germany). Various 
mesoporous silica particles (Table 1) with pores of 3 nm (Syloid® AL-1 FP), 6 nm (Davisil® 
LC 60 Å 12 µm), 10 nm (Syloid® 72 FP), 17 nm (Syloid® 244 FP), and 25 nm (Syloid® XDP 3050) 
were kindly provided by Grace GmbH & Co. KG (Worms, Germany). Ethanol, isopropanol, 
butanol, acetone, ethyl acetate, acetonitrile, and dimethyl sulfoxide (DMSO) in gradient grade 
were purchased from VWR (Darmstadt, Germany), and purified water was used produced by 
a Milli-Q system from Merck Millipore (Darmstadt, Germany).  
Table 1: Silica particles used and their properties according the certificate of analysis (manufacturer: company 
W. R. Grace & Co., USA). 
product code pore diameter 
[nm] 






Syloid® XDP 3050 25 300 1.8 50 
Syloid® 244 FP 17 380 1.6 3 
Syloid® 72 FP 10 370 1.2 5 
Davisil® SP53D 6 550 0.9 12 




To assess maximum solubility of rutin, rutin suspensions were prepared with different 
solvents (dimethyl sulfoxide (DMSO), ethanol, isopropanol, butanol, acetone, ethyl acetate, 
acetonitrile, and water) (n=1). The suspensions with 20% (w/w) rutin were shaken overnight 
at room temperature, centrifuged, filtrated and the rutin concentration in the filtrate was 
analyzed after dilution in ethanol (factor 100-1000) by UV spectrophotometry (UV-1700 
PharmaSpec, Shimadzu, China), at 360 nm. Evaluation was conducted by the provided 
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“UVprobe” software (version 2.21). Concentration was calculated based on calibration curves 
determined in ethanol.  
Loading of particles 
Prior to loading, the silica particles were dried in an oven at 120°C for at least 2 hours. The 
saturated rutin solution was produced by preparing a 2% (w/w) rutin suspension in ethanol 
(96 vol.%), heating it under agitation to 60 °C for 1 hour and subsequent filtration. After 
cooling, it was checked that no rutin crystals were precipitated. Rutin content was determined 
prior using the rutin solution for loading. For loading, 3 g silica particles were dispersed in a 
respective volume of rutin ethanol solution. The volume used depended on how much rutin 
should be loaded into the silica particles (increasing amounts of solution with increased % of 
loading). The suspension was stirred for 5 min to achieve a fine dispersion of the particles. 
Then the suspension was placed into a rotary evaporator (Büchi, Germany). Solvent 
evaporation took place at 40°C±2 °C and 150±10 mbar, until a film was formed on the wall of 
the evaporation flask. Evaporation time depended on the amount of solvents used 
(i.e. increased with increase of loading percentage). For removal/minimization of solvent 
residues, a secondary drying phase at 40°C +/- 2°C and 20 mbar was performed for 30 min. All 
fractions presented are weight fractions unless otherwise stated. Each loading for each type 
of silica was performed once. 
Differential scanning calorimetry (DSC) for crystallinity investigation 
The physical state of silica particles, rutin raw active agent powder and rutin smartPearls was 
investigated by differential scanning calorimetry (DSC 1, Mettler Toledo GmbH, Germany) and 
calculated by the provided STARe software (version 12.10b). Exact amounts between 1-5 mg 
rutin loaded silica based on the respective mass of rutin (aimed 0.5-1 mg) were weighted in a 
punctured 40 µl aluminum pan and sealed (n=1). Measurements were performed at a heating 
rate of 20 K/min between 25 and 300 °C under 80 mL/min nitrogen purge.  
Determination of amorphicity by X-ray diffraction (XRD) 
To determine the amorphous state and possible residual crystal fractions of rutin in 
smartPearls X-ray diffraction was performed using a Bruker D8 (Bruker, USA) (n=1). A scan 
rate of 0.02° (2=2-60°) was applied and the goniometer equipped with a Cu-anode 
(Ka=0.15406 nm) run with a voltage of 40 kV and current of 35 mA. 
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Light microscopy (LM) and scanning electron microscopy (SEM) 
Light microscope imaging was performed using a Motic Microscope BA210 (Motic 
Deutschland GmbH, Germany) with a Moticam camera and the Software Motic Images Plus at 
100, 400, and 1,000-fold magnification. Scanning electron microscopy (SEM) was performed 
at 10,000-fold magnification using a Zeiss DSM950 (Carl Zeiss AG, Germany). Samples were 
sputter-coated with gold-palladium in an argon atmosphere with 15-20 kV at 0.05 mbar for 
four minutes. 
Determination of recovery rate 
For photometric analysis, a precisely weighted amount of rutin loaded silica particles around 
25 mg was dispersed in 5 mL DMSO. DMSO was used because of the high rutin solubility in 
this solvent. After 10 minutes shaking and 10 minutes ultrasonication the suspension was 
centrifuged at 10,000 rpm for 10 minutes and an aliquot of the supernatant was diluted in 
ethanol by a factor 100. Absorption determination was performed at 360 nm wavelength by 
a PharmaSpec UV-1700 (Shimadzu, China). Peaks were evaluated using the PharmSpec 
software “UVprobe” (version 2.21). 
HPLC measurement of the same samples were performed using a Kontron 400 System 
(Kontron Instruments GmbH, Germany) equipped with a 20 µl loop and an Eurospere 100 C18 
(5 µm 250x4 mm) column at 25 °C. Determination was performed at 360 nm with 20:80 
acetonitrile: acetate buffer (pH 4.8, 0.1 mol/L) as mobile phase and a flow rate of 1.25 mL/min. 
Peaks were evaluated with the provided Software KromaSystem 2000 (version 1.82). 
Solubility determination of rutin dissolved from smartPearls 
Solubility of rutin raw active agent powder and rutin smartPearls were determined for one 
hour in 0.15 molar NaCl solution using in situ UV/VIS measurement (Sirius inForm®, UK) with 
a fiber optic and a path length of 5 mm. Therefore, the 0.15 molar NaCl solution was placed 
in a beaker. The aqueous phase was tempered to 25 °C. After calibration of the pH electrode 
and UV/VIS optic the sample was added manually and immediately after that the UV/VIS fiber 
optic for measurement. Spectra were corrected using the software providing the Tyndall 
Rayleigh correction function. Different concentrations of raw active agent powder and rutin 
smartPearls were investigated limited by a maximum overall absorption up to 2.5. pH was 
determined over the whole measurement period. 
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5.3. Results and Discussion 
5.3.1. Considerations for selection of the production method/variables 
The production method should yield a high loading of the pores and complete transformation 
of the active agent into the amorphous state; thus, co-grinding was excluded. Also excluded 
was supercritical CO2 due to production cost reasons, complexity of the process and costs of 
a production unit. The method should be desirably a one-step method. This excludes the 
impregnation-evaporation process, because in many cases one impregnation is not sufficient 
to reach the anticipated loading. Multiple steps are normally required. Thus, the immersion-
evaporation process was selected. 
Evaporation times of the solvent removal step ranged from 75 min to 180 min depending on 
the solvent volume. After the second drying step, the obtained free flowing dry powder was 
removed. In case of film forming on the glass wall, the film was removed from the wall using 
a spatula. Potential aggregates were de-aggregated by stirring the powder, potential 
aggregates were easily to disperse (Figure 1). 
 
Figure 1: From left to right: rutin-ethanol solution, silica dispersed in rutin solution attached to the rotary evaporator, 
after the first hour solvent evaporation and obtained loaded silica powder SP53D (right). 
The principle was to suspend the particles in an amount of solvent containing the total amount 
of active agent to be loaded into the pores of the particles. During the evaporation process, 
the concentration of the active agent increases, precipitation takes place continuing until 
complete removal of the solvent. It was hoped that precipitation should take place 
preferentially in the pores because of the largest available surface area. Minor precipitation 
on the outer side of the particles in a thin layer represents no problem, as long as the active 
agent on the surface stays amorphous. It is obvious that in addition to the inner surface in the 
pores, localization on the surface of silica particles takes place. To be avoided is the formation 
rutin solution silica dispersion




of crystals of active agent outside the particles. This was checked by light microscopy and 
scanning electron microscopy. 
To study the suitability of the process, silica particles differing in particle size, in pore diameter 
and pore volume were selected (Table 1). The investigation should also give evidence, which 
particle type is optimal regarding achieved maximum loading, and being most easy to process. 
5.3.2. Solubility of rutin in solvents 
A compromise had to be made between solubility for rutin as high as possible and the 
tolerability of the solvent by the skin. Further, processing parameters such as evaporation 
temperature were crucial. DMSO was used in previous studies with the impregnation 
evaporation method [24] because it has high solubility and thus reduces the number of 
loading steps. Disadvantage was the long time period for solvent removal at high 
temperatures (>80°C) which can cause degradation of active agent. In addition, it is tedious to 
remove DMSO efficiently by rotary evaporation. Despite DMSO can be contained in products 
applied to the skin, it is less skin friendly. Efficient removal of critical solvents below the ppm 
specification is also a cost factor in the production process. Thus, a different, better tolerable 
solvent was desirable. 
Table 2 shows the obtained solubility of rutin in the various tested solvents. Rutin has highest 
solubility in DMSO (17%), as expected, but it was decided to select ethanol as compromise. 
With a maximum of 2%, rutin solubility is substantial lower than in DMSO but distinctly higher 
than e.g. in acetone (0.8%) and the other organic solvents. The rutin ethanol solution showed 










DMSO 17.05 brown 
ethanol 2.09 clear, bright-yellow 
n-butanol 2.07 clear, bright-yellow 
isopropanol 1.85 clear, bright-yellow 
acetone 0.83 pale yellow 
ethyl acetate 0.42 mildly cloudy 
acetonitrile 0.22 mildly cloudy 
water 0.03 cloudy, slight yellow 
 
5.3.3. Loading Process of silica particles, powder appearance 
Different silica from Table 1 were loaded with rutin by dispersing them in saturated rutin 
ethanol solution, evaporating the solvent in a rotary evaporator, until dry powders were 
obtained. Nitrogen ad-/desorption studies were performed showing little decrease in pore 
diameter, but reduction of the pore volume supporting the bottom to up filling of the 
pores [32; 33]. Depending on the particle size and the pore diameters, the powders showed 
different macroscopic appearance. The silica AL-1 FP tended more towards aggregate 
formation, they possess particle size of 7 µm and smallest pore diameter (3 nm). 244 FP and 
72 FP showed slight agglomeration (particle size 3 and 5 µm, resp; pore diameter 10 and 
17 nm). SP53D with medium size of 12 µm showed almost no agglomeration, at higher loading 
of 28% and 30% a film formed on the wall of the evaporator glass, respectively. The XDP 3050 
particles with largest size of 50 µm (pores 25 nm) showed neither agglomeration nor film 




Figure 2: Macroscopic appearance of loaded silica powders, from left to right with decreasing agglomeration 
tendency (explanations cf. text). 
It can be summarized, that silica particles get more adhesive with decreasing size, easily 
explainable by powder technology. The surface and contact area increase, thus promoting 
particle-particle interaction. Additionally, with increasing pore diameter decreased the 
agglomeration tendency. The particles with clear agglomeration tendency (AL-1 FP) have 
smallest pore size of 3 nm, and additionally smallest pore volume. It is assumed that the pore 
parameters play only a significant role in agglomeration tendency in case pore volume is 
completely filled with active agent or pores are too small, that means an overloading takes 
place and precipitating active agent acts as a kind of glue between silica particles. This was 
assumed for the AL-1 FP samples since rutin with a molar weight of 610.5 g/mol and a 
minimum projection area of 9.2 nm2 was assumed to be oversized to diffuse efficiently into 
the pores prior precipitation. Thus, such small pores promote agglomeration outside of the 
pores. Based on the behavior observed, silica particles with larger size, pores and pore volume 
are easier to process on large scale.  
5.3.4. Determination of amorphous content by DSC and X-ray 
Amorphicity determination of the loading was performed in parallel by DSC and X-ray 
diffraction. An amount of 5% rutin in the physical mixture with amorphous unloaded silica was 
detectable by DSC. Analysis of physical mixtures of silica with crystalline rutin powder showed 
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that an amount of only 3% crystalline rutin was clearly detectable by X-ray, 1.5% were hardly 
detectable (X-ray diffractogram not shown). 
Figure 3 shows the DSC thermograms for maximum loaded silica SP53D, loaded with different 
solvents, compared to unloaded silica, rutin and their physical mixture. In the physical 
mixture, 5% rutin were clearly detectable. No rutin peak was detectable for loadings up to 
25% with ethanol, 28% with butanol and 35% with DMSO. Crystalline rutin was clearly 
detectable for 28% loading with ethanol (detectable in temperature range of 175-190°C). 
From this was concluded that the limit of loading in the amorphous state was achieved at 25% 
with ethanol as solvent. As reported from Jin N. et al. loadings of 32% are achievable with 
DMSO and the impregnation evaporation method [24]. Same loading or even higher can be 
reached by the immersion evaporation method, thus they are at least even efficient. However, 
the immersion evaporation method is scalable and thus of more practical relevance. Since 
DMSO is a hardly processable solvent and more expensive than ethanol, loading of 25% is 
favored, reached with the use of ethanol. 
 
Figure 3: DSC thermograms of crystalline rutin, amorphous unloaded silica, physical mixture (5% rutin) in 
comparison to SP53D loaded with ethanol (28% and 25%), butanol (28%) and DMSO (35%).  
Figure 4 shows X-ray diffraction patterns of rutin in comparison to unloaded amorphous silica, 
crystalline rutin and their physical mixture. The respective X-ray diffraction patterns of rutin 
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loaded SP53D silica and ethanol (25% loading), butanol (28% loading) and DMSO (35% loading) 
as solvent revealed the amorphicity of these samples. A rutin peak was detectable in the 
physical mixture with 3% rutin. Peaks were only detectable for SP53D loaded with 28% rutin 
and ethanol as solvent, being in agreement with the DSC data. Even the high loading up to 
35% (loaded with DMSO) was stable amorphous. As mentioned, the industrial feasibility is 
more important than a maximum achievable loading. To be on the safe side, 20% loadings 
produced with ethanol were used for determination of the saturation solubility and is 
recommended as maximum for commercial use.  
 
Figure 4: X-ray diffractograms of rutin, unloaded silica (SP53D), physical mixture (3% rutin) in comparison to the 
maximum loading with silica SP53D loaded with different solvents (ethanol, butanol, DMSO). 
Figure 5 shows a comparison between all investigated silica, DSC curves (left) and X-ray 
diffraction patterns (right), the curves are plotted with the highest achievable amorphous 
loading for each silica type, showing no peaks. Only for 72FP, the curve with no peaks (20% 
loading), and the curve with peaks are plotted (system overloaded, 25%). For AL-1 FP, the 
silica with smallest pore size (3 nm) only overloaded curves are shown (12% and 15%). The 
comparison between DSC and X-ray shows, that X-ray was more sensitive. In all overloaded 
systems detected by peaks in X-ray, no peaks could be seen in DSC. Thus, applying both 
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methods in parallel was sensible. In conclusion, silica with very small pore size of 3 nm are less 
suited. The loading of the other silica was generally between 15% and 25%. 
 
Figure 5: DSC thermograms (left) and X-ray diffractograms (right) for selected investigated silica, all loaded with 
ethanol as solvent for rutin, showing curves with highest amorphous loading (no peaks). For 72 FP 
(10 nm pores) also the curves obtained with the overloaded system (25%) are shown, for AL-1 FP only 
overloaded curves are presented (pore size 3 nm, 12% and 15% loading). 
5.3.5. Light microscopy and scanning electron microcopy (SEM) 
Light microscopy is readily accessible and fast to perform; thus, it was also used to follow the 
process of increasing loading. In case rutin crystals appear besides the silica particles, they 
should be easily detectable. Also, it was expected to see changes on the surface of the silica, 
i.e. deposition of rutin. Figure 6 (upper) shows exemplarily the XDP 3050 particles. Unloaded 
the silica appear clearly translucent (upper left), loading rutin into the pores leads to darkening 
of the particles (upper middle). Apparent is, that some particles are still relatively translucent, 
other particles are slight to medium dark, also very dark particles can be seen. That means not 
all particles are loaded to the same degree, there is a loading distribution between the 
particles from slightly to heavily loaded. This is important for understanding the process. 
When adding more rutin solution, the heavily loaded particles will first show a crystalline 
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fraction (rutin crystallizing on the surface). The overloaded system with 20% rutin (upper right) 
shows a majority of dark particles. 
 
Figure 6: Upper: light microscopy images of silica XDP 3050 unloaded (left), loaded with maximum amorphous 
fraction of 18% (middle) and overloaded silica (20% rutin, right). Lower: corresponding SEM images 
(from left to right). 
In Figure 6 (lower), the SEM images of unloaded silica shows a smooth surface, almost free of 
adhering fine particulate material (lower left). The maximum loaded particles (lower middle) 
show some fine particulate material on the surface. From light microscopy it is known, that 
there is a distribution in the degree of particle loading. Thus, the problem in SEM analysis is 
to distinguish to which particles the microscope is focusing on. In light microscopy one gets 
the overview with one glance. In the sample XDP 3050 with overloaded silica (20% loading), 
particles can be found with pronounced fine particulate material on the surface of some 
50 µm silica particles. 
In conclusion, light microscopy is a suitable complementary tool for following the loading 
process, SEM gives some more visual insight of basic academic understanding, but is not 
essential for monitoring an industrial production process.  
Based on these analyses, a mechanism of loading is proposed (Figure 7), example is a silica 
with 1.8 mL pore volume per gram. At the beginning before loading, all pores are empty – 
represented by the bar at 0 mL/g filled (Figure 7, upper, left bar). As seen from the light 
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microscopy images – after the loading process, obviously some particles remain unfilled (light 
particles), some are medium filled, some are heavily filled (very dark particles). This is 
represented in Figure 7, middle. Penetration of solvent is different into different particles, 
leading to particles remaining not filled (low bar at 0 mL/g filling) or particles little or medium 
filled (bars at 0-0.4 and 0.4-0.8 mL/g, resp.) There are also particles with higher pore volume 
filling (0.8-1.2 and 1.2-1.8 mL/g). There are also particles with completely filled pores (filled 
volume 1.8 mL), which have additionally rutin on the surface, that means the rutin volume per 
gram particles is >1.8 mL (Figure 7, middle, right bar). This surface amount is amorphous, since 
no crystallinity is detected. 
In case too much rutin solution is used, and evaporation continues, rutin continues to 
precipitate on the surface of completely loaded particles. By rutin deposition in thin layers on 
the surface, the rutin stays amorphous, with increasing layer thickness above a critical 
threshold crystallization occurs, being detectable by DSC/X-ray (Figure 7, lower, right bar). For 
the performance of the particles on the skin one could discuss, if even overloaded systems 





Figure 7: Mechanism model of loading of the silica particles, distribution of differently filled particles as function of 
increasing loading. The fractions of particle with “different loading levels” are plotted (0, 0-0.4, 
0.4-0.8 mL/g etc.). Upper: in unloaded state all particles are in the 0 fraction. Middle: maximum loading 
with no detectable crystallinity, particles are filled to a different extend, possibly including a minor number 
being overloaded (>1.8 mL/g, but no detectable peaks in X-ray). Lower: Particles are overloaded, the 
population contains a particle fraction in which detectable crystallization occurred (details cf. text). 
5.3.6. Loading efficiency – recovery rate 
It was investigated if the nominal content of rutin in the different particle types could be 
recovered. The rutin was extracted with solvent, and the content determined by 
spectrophotometry and HPLC. The coefficient of determination was 0.9943 for HPLC and 





















































the two silica SP53D and 72 FP, with increasing loading from 20% to 30%. Silica SP53D and 




Figure 8: Recovered fraction of rutin after extraction of silica SP53D (left) and 72 FP (right) with increasing loading 
of 20%, 25%, 28% and 30% measured with HPLC (blue) and spectrophotometry (green). Standard 
derivation is shown for mean of all measurements (HPLC n=2, UV n=1). 
At lower loadings (20%, 25%) a minor fraction could not be recovered. It is reported in the 
literature, that due to the large surface area, a delayed release takes place, some active agent 
is quite firmly bound to the surface area and is thus not released [34]. Thus, absolute retrieved 
amount increases in percentage with increasing loading. Additionally, remarkable was the 
higher recovery rates for samples with a certain crystallinity. This could explain the higher 
recovery rate at higher loadings of 28-30%. Silica with smaller pores (3 nm, AL-1 FP) showed 
at low maximum loading (12%) and a recovery rate of about 35% only. Analysis of the recovery 
rate was also performed by HPLC, the data are all slightly below the spectrophotometric 
results but are in agreement as shown in Figure 8. 
Different results from the UV spectrophotometry and the HPLC analysis can be explained by 
the extraction times applied for HPLC and UV spectrophotometry samples. In general, a higher 







recovery rate was found in spectrophotometry analysis due to a 2 hours prolonged extraction 
time (about 30 minutes for HPLC analysis versus 2 hours). The incomplete release from small 
pores and the influence of time has relevance for the in vivo situation. Often dermal 
formulations are applied for 10-12 hours (morning application onto the face, face wash in the 
evening). To have a release as complete as possible, larger pores are thus favorable for dermal 
products. Apart from the consequence for dermal delivery, the data show that for better 
comparison of data, the extraction procedures need to be exactly Identical. 
5.3.7. Solubility determination of rutin dissolved from smartPearls 
The saturation solubility reported from Mauludin et al. for rutin nanocrystals and rutin as raw 
material is about 130 µg/mL [35]. The solubility of the raw active agent powder is thereby 
attributed to a minimal content of nanosized rutin particles in the raw material used. 
Measuring the solubility of the rutin raw powder with the setup used in this study yielded 
saturation solubilities from 30 to 70 µg/mL at pH 5.5±0.5 (Figure 9 lower curves). Temperature 
was thereby constant at 25 °C. Apart from content of nanosized material, the general high 
values reported in literature can be attributed to a higher pH (6.8) and temperature (37°C) 
than used in this study (pH 5.5 for skin products and 25°C). Additionally, the in situ 
measurement with baseline correction and the used 0.15 molar NaCl solution had an 
influence on the difference to the values reported in literature. The theory that a minimal 
content of nanosized rutin particles are present in the raw material is supported by the fact, 
that the measured Cs increased from 30 to 70 µg/mL with increasing amount of rutin powder 
added to the solvent (from 0.28 mg/mL to 2.03 mg/mL), i.e. adding increasing amounts of 




Figure 9: In situ determined saturation solubility of rutin raw active agent powder (lower curves, red) and 
amorphous rutin loaded in smartPearls (upper curves, green) with various rutin concentrations. 
In contrast to the rutin powder, in this study an increased Cs of about 160 µg/mL was obtained 
with amorphous rutin dissolved from smartPearls, that means about factor 2 higher than the 
respective raw active agent powder. This higher Cs leads to an increased concentration 
gradient between dermal formulation and skin, thus to an increased flux into the skin.  
The dissolution kinetics of rutin from the smartPearls is much faster than from the raw rutin. 
With smartPearls, the plateau of solubility is practically reached after 1 minute, for the raw 
rutin it takes 5-10 min. However, for the dermal formulation the kinetics is not relevant, only 
the saturation solubility Cs. The smartPearls are added in the preparation of the dermal 
formulation, and a saturated state will occur in the formulation. It does not matter if this takes 
1 or 10 min. When applied to the skin, it can be predicted, that the rate limiting step is the 
slow diffusion of dissolved rutin into the skin. There will be no difference if the diffused rutin 
molecules are replaced in the dermal formulation by faster or slower dissolution. 
 





























In vitro skin penetration studies showed an even higher increase in penetration comparing a 
gel with smartPearls to a gel with rutin powder (pig skin penetration test, tape stripping [24]). 
Especially in the deeper skin layers, an increase by a factor of about 4 was observed.  
5.3.8. Concentration of smartPearls in final market products 
When adding smartPearls to the water phase of a dermal product, a part of the rutin in the 
pores will dissolve, forming a supersaturated solution. A part has to remain undissolved in the 
pores, to provide a rutin depot. When dissolved rutin in the water phase has penetrated into 
the skin, it should be replaced by new rutin molecules dissolving from the pores. By this a 
constant supersaturated state will be maintained. Based on this, the rutin concentration 
required for a dermal product can be calculated. 
The measured saturation solubility of rutin from smartPearls is 150 µg/mL, i.e. 0.15 mg/mL. 
This will be the amount which dissolves when adding the smartPearls to the formulation. In 
addition, one needs a rutin depot in the pores. Thus, it is recommended to use about minimum 
two times the amount dissolved. In cases of highly penetrating active agents, the required 
depot amount might even be higher. Based on this, a minimum of about 0.5 mg/mL final 
product is required. Assuming a low loading of the pearls of 10% (w/w), a total of 5 mg loaded 
smartPearls need to be added per mL (g) product (i.e. 5 g/1 kg product). 
5.3.9. Definition of production parameters for large scale 
Based on this, producing a batch of 100 kg requires 500 g smartPearls, with assumed only 10% 
loading this corresponds to 50 g rutin powder. In the production process, this 50 g rutin have 
to be dissolved in ethanol. Based on an ethanol solubility of 2%, 2.5 kg ethanol are required. 
In this rutin solution, 450 g unloaded silica particles are dispersed. For evaporation, a rotary 
evaporator with about 2.5 L solvent evaporation capacity is required, i.e. a rotary evaporator 
with a volume of about 20 L. 
Large rotary evaporators are available up to volumes of 200 L (e.g. from GlasKeller AG, Basel, 
Switzerland). That means in one loading process 5 kg smartPearls sufficient for 1000 kg final 




For best monitoring of the loading process a combination of DSC, X-ray and light microscopy 
is most suitable. In this study, X-ray was proved more sensitive than DSC. 
Particles were obtained showing a maximum amorphous loading of 25% loaded with ethanol. 
With DMSO a loading of up to 35% was reachable. Thereby DMSO is hard to remove because 
of its high boiling point. However, ethanol is preferable because of its better tolerability, price 
and better technical processability. 
To ensure complete amorphization a loading of 20% rutin is recommended. Re-crystallization 
was detected first at loadings of 28%, thus 20% is far below. Saturation solubilities increased 
by factor 2 with just one tenth amount of amorphous rutin compared to raw active agent 
powder. 
Light microscopy contributed to the understanding of the loading process. It nicely revealed 
that filling the pores follows a distribution of filling degree (unloaded to highly loaded). Only 
a part of the particles reaches complete loading, these are the particles which might show first 
crystalline fractions. 
Regarding ease of process-ability: Small particles such as AL-1 FP (7 µm) – as predictable - tend 
to more adhesiveness, and in combination with the small pore size of 3 nm maximum loading 
is low (< 12 %). Favorable for loading are larger particles with larger pores and pore volume, 
most favorable is Syloid® XDP 3050.  
Due to the solubility properties, the amount of 5 kg loaded smartPearls for a ton of final 
product is relatively low, and – with the established basic process – should be able to be 
producible in commercially available industrial 50 L evaporators (i.e. is scale-able. To imitate 
exactly the situation in the large scale studied on small scale, just temperature and vacuum 
need to be set this way, that the same amount of solvent evaporates per time unit (i.e. copying 
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6. Glabridin smartPearls – Silica selection, production, amorphous 
stability and enhanced solubility5 
Abstract 
Glabridin, a compound in the root extract of Glycyrrhiza glabra, has been identified as an 
effective tyrosinase inhibitor. Applied on skin, melanin synthesis is inhibited, making glabridin 
an interesting candidate for skin whitening or for the treatment of age spots. However, main 
obstacle for its practical use is its low dermal bioavailability, caused by its poor water solubility 
(1-20 mg/L). In this work smartPearls technology was used to increase the glabridin’s water 
solubility. smartPearls consist of silica particles with mesopores in which actives can be 
loaded. By this, actives are stabilized in amorphous state and simultaneously finely distributed 
in nm-range. Both amorphization and nanoization are well known approaches to increase 
saturation solubilities. In smartPearls these approaches are combined. In the first step, 
glabridin smartPearls formulation was developed, screening systematically the suitability of 
4 different silica varying in their pore sizes (3, 6, 10, 17 nm). Also, most suited filling level of 
glabridin was determined (25, 50, 80% referred to total pore volume of respective silica). Silica 
loading was performed by the immersion-evaporation method, resulting in pores filled with 
glabridin from bottom to top. By light microscopy, differential scanning calorimetry and X-ray 
diffraction the sample with 6 nm pore size and filling levels of 25% and 50% have been verified 
to be completely amorphous. Highest physical storage stability of 7 months up to now was 
obtained for the 25% filled sample. In the next step, concept of increased saturation solubility 
for smartPearls was proven. Dissolution profiles were recorded in situ for glabridin 
smartPearls and compared to glabridin raw drug powder. Both saturation solubility and 
dissolution velocity were remarkably improved. The water solubility for example increased by 
a factor of more than 4. This makes glabridin smartPearls promising for creating skin products 
with improved dermal bioavailability.  
  
                                                        
5  This chapter has been published as: 
Hespeler, D.; Kaltenbach, J.; Pyo, S.M.; 2019. Glabridin smartPearls – Silica selection, production, amorphous 





Glabridin is a chemical compound that is found in the root extract of Glycyrrhiza glabra. Since 
its characterization in 1976 increasing number of publications reports its various biological 
effects, e.g. anti-oxidative, anti-inflammatory, neuroprotective and skin whitening effects [1]. 
Therefore, Glabridin can be of interest not only as pharmaceutical active but also as cosmetic 
agent [2].  
Especially as skin whitener glabridin is of interest for the Asian cosmetic market, as bright skin 
is the ideal of Asian beauty. But also, for the European cosmetic market glabridin can be of 
interest for age spot treatment. Both tanned skin and age spots have in common that this area 
of skin is rich in melanin. Synthesis of the skin pigment melanin is triggered by UV light. It 
activates the enzyme tyrosinase, which converts tyrosine stepwise to melanin [3]. Glabridin, 
one main active component of the root extract, is an efficient inhibitor of tyrosinase. Yokota 
et al. [4] reported, that skin pigmentation induced by UVB radiation on the backs of the 
brownish guinea is significantly reduced (34% inhibition over control) when glabridin is 
topically applied as a 0.5% solution in ethanol/propylene glycol/water (6.5/2.5/1.0).  
However, only a small number of glabridin containing products exists on the cosmetic market. 
One reason limiting its use can be its low water solubility (1.5 mg/L, estimated by EPISuite [5] 
or 20 mg/L by ChemAxon [6]). Skin penetration is a passive diffusional process. The amount 
of penetrating active is therefore directly proportional to the concentration gradient between 
formulation and skin. Hence, the low solubility results in low bioavailability. A simple increase 
of glabridin amount for compensation is practically not realizable due to the high glabridin 
prize of 20 USD per gram [7]. This explains the numerous publications dealing with the 
penetration enhancement of glabridin. One commonly reported approach is the increase of 
glabridin’s lipophilicity by esterifying or etherifying one or both hydroxyl groups of 
glabridin [8-10]. However, the whitening effects is coupled to these hydroxyl groups, and 
masking either one or both leads to distinctly reduced efficacy [4]. Hence, chemical 
modification is not a meaningful method [11]. Increasing the penetration can be also 
implement by physical modifications improving the water solubility. One well-known solubility 
increasing approach is the reduction of the crystal size to the nano-dimension [12]. These so-
called nanocrystals of glabridin were already invented by PharmaSol GmbH, Berlin and are 
commercially available.  
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A recently invented physical transformation is the formation of glabridin smartPearls [13]. 
smartPearls consists of regulatory accepted mesoporous silica particles (up to 50 µm) with 
pore widths between 2 and 50 nm. In these pores, actives can be loaded and long-term 
preserved in amorphous state for up to 7 years [14]. Since amorphous state is 
thermodynamically unstable and tend to re-crystallize within few days or months, 7 years is 
remarkable. Hence, loaded active in smartPearls combines two principles of solubility 
increase [15]. 
1) dispersion of active in nm-range comparable to nanocrystals, and  
2) stabilized amorphous state of active.  
This combination of two saturation solubility increasing principles may explains why 
smartPearls are reported to be even superior to the current “gold standard” nanocrystals, only 
working with one principle. In comparative studies with poorly soluble anti-oxidants, 
e.g. hesperidin, smartPearls possessed a 5-times higher saturation solubility than 
nanocrystals [16]. Similar observations were made for their penetration in an ex vivo 
investigation on porcine ears by the tape stripping method. The penetrated amount of 
azithromycin from smartPearls was up to 30-times higher in the deeper layers of the stratum 
corneum (represented by tapes 20-30) than for nanocrystals [16]. Therefore, smartPearls 
appear promising in improving the penetration of poorly soluble glabridin into skin – even 
better than the nanocrystals currently available on the market. 
Therefore, aim of this study was to develop a physically and chemically long-term stable 
glabridin smartPearls formulation. This formulation should enable market formulations with 
improved skin penetration by simultaneously decreased costs. Therefore, 4 different silica 
with different physical properties, e.g. pore widths (3, 6, 10 and 17 nm), were selected. Each 
of the silica was then loaded in 3 different filling levels (25, 50 and 80% of total pore volume) 
to examine if the filling level has an influence on amorphization and its preservation. All 
loadings were performed by the immersion-evaporation method [17], and its suitability for 
loading the chemically sensitive glabridin in mesoporous silica was verified by HPLC analysis. 
Also, the question was answered, how the glabridin is located in the pores, since localization 
will influence its release. Finally, for proving the concept of increased solubility by smartPearls, 
the saturation solubility of stable glabridin smartPearls formulation was measured and 
compared to the saturation solubility of glabridin raw drug powder.  
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6.2. Materials and Methods  
6.2.1. Materials 
Glabridin with a high purity of 98% was purchased from Actives International (Allendale, USA). 
Various mesoporous silica particles were kindly provided from Grace GmbH & Co. KG (Worms, 
Germany), and are listed in Table 1 with their respective physical properties. Ethanol in HPLC 
grade was purchased from VWR (Darmstadt, Germany), and purified water was used 
produced by a Milli-Q system from Merck Millipore (Darmstadt, Germany).  
Table 1: Overview of mesoporous silica used in this study with respective physical properties [18]  








Syloid® AL-1 FP 3 0.4 740 7 
Davisil® LC60A 6 0.9 550 12 
Syloid® 72 FP 10 1.2 370 5 
Syloid® 244 FP 17 1.6 380 3 
 
6.2.2. Methods 
Density determination by helium pycnometer 
In this study, the production of smartPearls with glabridin loadings of 25, 50 and 80% (related 
to the total pore volume of respective silica) were aimed. Since the loading is related to the 
volume, but mass is needed for weighing glabridin and silica, densities of both were 
determined in advance using a helium pycnometer AccuPyc II 1340 (Micromeritics Instrument 
Corp., Norcross, USA). In a 1 cm3 sample cell 0.25 g of either glabridin or silica were weighted 
and purged 20 times with helium. One sample was measured for 5-times and the resulting 
average was used for subsequent calculation.  
Production of glabridin smartPearls 
For loading by immersion-evaporation method, the active first had to be brought in solution. 
For glabridin smartPearls, which will be used on skin, ethanol was selected as solvent and 
10% (w/w) glabridin solutions were prepared. Then, 2 g of silica was weighted into a 250 mL 
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round-bottom flask and required amount of this solution to obtain desired loadings of 25, 50 
or 80% was added (Table 2). By rotating the flask using a rotary evaporator (Büchi 
Labortechnik GmbH, Germany) without applying heat or pressure, glabridin solution was 
thoroughly mixed with silica. As next step, ethanol was removed stepwise, first at 40±2°C and 
150±5 mbar, then below 50 mbar. To obtain completely dry and free flowing glabridin 
smartPearls, additional drying step was implemented using a desiccator under vacuum 
(<20 mbar) for 12 hours. 
Table 2: Overview of 10% ethanolic glabridin solution needed for loading 2 g silica at pore volume loadings of 




10% ethanolic glabridin solution [g] added to  
2 g silica to obtain following PV loadings: 
 [mL/g] 25% PV 50% PV 80% PV 
Syloid® AL-1 FP 0.4 not produced 5.20 6.24 
Davisil® LC60A 0.9 5.85 11.71 18.72 
Syloid® 72 FP 1.2 7.80 15.60 24.96 
Syloid® 244 FP 1.6 10.40 20.80 33.28 
 
Characterization of glabridin smartPearls 
High performance liquid chromatography (HPLC)  
The glabridin content in loaded smartPearls were investigated directly after production and 
after 6 months storage at room temperature. 50 mg glabridin smartPearls were dispersed in 
10 mL ethanol. To dissolve glabridin completely from smartPearls, the dispersion was 
extensively shaken and sonicated for 10 minutes. By centrifugation silica fraction was 
separated. The so obtained glabridin solution was diluted for measurement by a factor of 125. 
Measurement was performed using a Kontron 400 System (Kontron Instruments GmbH, 
Germany) equipped with a 20 µl sample loop and an Eurosphere 100 C18 (5 µm 250x4 mm) 
column. The mobile phase consisted of a 57:43 mixture of 2% acetic acid and acetonitrile, 
respectively. Flow rate was set to 1.2 mL/min, column oven to 30°C and detector wavelength 
to 282 nm. The peak evaluation was carried out by the supplied software KromaSystem 2000. 
Retention time of glabridin was 12 minutes. By applied measurement settings, the limit of 
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detection was determined to be 0.24 µg/mL and the limit of quantification 0.72 µg/mL with a 
slope of 0.2947 and a standard deviation of 0.0213. 
Light microscopy (LM) 
Under light microscope both shape and size of smartPearls were investigated before loading, 
directly after loading and after storage at room temperature for 1 week, and 1, 3 and 
6 months. Therefore, the Motic BA210 LED was used at 100, 400 and 1000-fold magnification 
and photos were taken by Moticam 3.0 MP (both from Motic Deutschland GmbH, Germany).  
Differential scanning calorimetry (DSC) 
The physical state of silica particles, glabridin raw drug powder and glabridin smartPearls was 
exanimated by differential scanning calorimetry (DSC 1, Mettler Toledo GmbH, Germany). In 
a punctured 40 µl aluminum pan exact amount between 1-10 mg were weighted, based on 
the respective mass of glabridin. Measurements were then performed at a heating rate of 
20 K/min between 20 and 280°C.  
X-ray diffraction (XRD) 
In addition, X-ray diffraction were performed using a Bruker D8 (Bruker, USA) to determine 
the amorphous state and possible residual crystal fractions of glabridin in smartPearls. 
Measurements were carried out after production and 7 months of storage at room 
temperature. A scan rate of 0.02° (2=2-60°) was applied and the goniometer equipped with a 
Cu-anode (Ka=0.15406 nm) run with a voltage of 40 kV and current of 35 mA. 
Nitrogen ad- and desorption 
After outgassing samples for 24 hours at 30°C, nitrogen isotherms were recorded with 
20 measurement points of adsorption and 24 points of desorption using a NOVA 
Quantachrome 4000e (Quantachrome GmbH & Co. KG, Germany). The so obtained isotherms 
were evaluated with supplied NOVAwin 11.0 software. Surface areas were determined after 
the Brunauer-Emmett-Teller (BET) method [19], and pore widths and pore volumes after the 
density functional theory (DFT) [20]. 
Determination of saturation solubility 
The saturation solubility was assessed for best glabridin smartPearls formulation and raw drug 
powder using a Sirius inform (Sirius Analytical Instruments Ltd., Forest Row, UK). This devise 
allows in situ UV/VIS measurements of the samples. All tests were performed for 30 minutes 
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aqueous NaCl solution (0.15 N) at 25 °C. Non-sink conditions were selected with glabridin 
amounts 10 times higher than the saturation solubility of glabridin from literature. Tyndall-
Rayleight scattering occurring due to unsolved particles were corrected by aligning the 
spectrum between 400 and 500 nm [21]. 
6.3. Results and Discussion 
6.3.1. Pre-considerations and explanations 
Selection of silica for smartPearls production 
Theory behind amorphous preservation in mesoporous particles is the so-called “space 
restriction principle”. For re-crystallization certain space is needed by the active which the 
pores do not provide. Selecting the correct pore size will therefore be decisive for 
preservation. According to Sliwinska et al. [22], the ratio of silica pore width to active molecule 
size must be smaller than 12 for an efficient preservation of amorphous state. For ratios being 
between 12 and 20, amorphous state can be obtained and may preserved. And ratios greater 
than 20 considerably tend to re-crystallize. According molar volume of glabridin 
(257.9±3 cm3), a spherical diameter of 0.94 nm was assumed. Hence, for the desired ratio of 
either <12 or <20, pore widths of <11.6 or <19.4 are needed. Therefore, 3 silica providing the 
required ratio <12 were selected (pore width of 3, 6 and 10 nm) for this study. In addition, one 
silica being between the ratio of 12-20 were chosen (pore width of 17 nm) may allowing the 
production of stable smartPearls with considerably higher glabridin content.  
Sample name 
Glabridin smartPearls samples produced in this study varied in used silica and loaded amount 
of glabridin. Hence, samples were named after these two characteristics following the 
pattern: “Pore size of silica in nm – loading in volume percentage”. Sample 6-25% for example 
is produced by filling 25% of total pore volume of Davisil® LC60A with glabridin.  
Calculation of glabridin mass fraction 
3 different pore volume loadings of 25%, 50% and 80% were selected to gain a better 
understanding of the pore stabilization mechanism. However, for loading process, respective 
glabridin to silica mass ratios were needed for correct weighing. Also, the glabridin fraction is 
crucial for dosing glabridin smartPearls in final formula, e.g. creams or gels. To calculate the 
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glabridin mass fraction in each sample, the densities of silica and glabridin were determined 
in advance to be 2.14 g/mL and 1.32 g/mL, respectively. The resulting mass fractions for each 
sample are listed in Table 3. After calculation, sample 3-25% was withdrawn, as this pore 
volume loading would have led to a glabridin mass fraction <20% being insufficient for 
practical use.  
Table 3: List of glabridin mass fraction for all prepared samples in this study. To clarify the difference to the mass 
fraction %, the pore volume % was named as PV in the list.  




glabridin content in mass fraction [% (w/w)] 
calculated for desired 3 pore volume loadings: 
 [nm] [mL/g] 25% PV 50% PV 80% PV 
Syloid® AL-1 FP 3 0.4 -/- 20.9 29.7 
Davisil® LC60A 6 0.9 22.9 37.3 48.7 
Syloid® 72 FP 10 1.2 28.4 44.2 55.9 
Syloid® 244 FP 17 1.6 34.6 51.4 62.8 
 
6.3.2. Characterization of glabridin smartPearls  
Preselection by light microscopy  
To get a quick first impression of freshly produced glabridin smartPearls, light microscopy (LM) 
is ideally suited. It allows to preselect samples for further investigations being more time 
consuming and costly, e.g. nitrogen ad- and desorption or DSC. If the majority of glabridin is 
firmly loaded in the pores, no change can be observed in their appearance. An example for 
firmly loaded glabridin is given in Figure 1. On the left, LM image of unloaded silica with 6 nm 
pore width is shown at 1000-fold magnification. On the right, same silica with pore volume 
loading of 50% is shown. No visible changes occurred. In contrast, overloaded samples show 
newly formed smaller crystals in addition to the silica. As example, 3-80% glabridin 
smartPearls are shown in Figure 1 right. Compared to the unloaded silica, formation of new 
crystals is visible. Hence, these samples can be dropped out. Even though LM can be used for 
preselection, no change in appearance is no guarantee for firm inclusion. These samples need 
further investigation by e.g. XRD or DSC for reliable evidence. 
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After intensive evaluation of LM images, all samples with 3 nm pore width were excluded from 
further investigations. All other samples looked inconspicuous, even all silica samples with 
17 nm pore width.  
 
Figure 1: Light microscope images at 1000-fold magnification of unloaded samples 6-0% (left), and loaded 
samples 6-50% (middle, showing no visible changes) and 3-80% (right, showing additional crystals of 
unloaded glabridin).  
Proof of absence of crystalline glabridin fractions by DSC 
By DSC measurements, a more sensitive determination of crystalline fractions is possible [23]. 
The detection limit of glabridin was determined by measuring the physical mixture of glabridin 
raw drug powder with silica particles at various ratios to be 1% (Figure 2, lower graph).  
The DSC thermogram of glabridin raw drug powder showed an onset temperature of 229 °C 
and a melting peak at 232 °C (Figure 2, middle graph). In contrast, the DSC thermogram of 
unloaded silica showed no melting peaks (Figure 2, upper graph). Only a broad peak around 
100°C was detected representing adhered water on silica surface. This peak appeared also for 
loaded silica (Figure 3). As no shift of this water peak to lower temperatures occurred it can 
be concluded that no detectable amount of ethanol (boiling point ~80 °C) is left in the sample. 
Hence, the applied drying process is suited to remove the solved completely.  




Figure 2: From upper to lower: DSC thermograms of silica particles with pore width of 10 nm, glabridin raw drug 
powder, and a physical mixture of 1% glabridin raw drug powder and 99% silica particles.  
In addition to the expected glabridin melting peak at 232 °C an additional peak at 216 °C was 
observe for the physical mixture. Since this peak is absent in the thermogram of pure raw drug 
powder, even the very gentle blending of the silica with glabridin raw drug powder seems to 
cause a change in glabridin’s crystallinity. Since no pressure nor temperature was applied to 
prepare this blend, the peak seems to be caused most likely by surface interactions. As the 
melting point is lower (216 °C) than the melting point of raw drug powder (232 °C), a 
thermodynamically more instable form seems to be created. However, by present data no 
certain statement can be made what exactly is formed.  
Conceivable is the transformation of glabridin into more thermodynamically unstable 
crystalline form. Also possible is a fractional transformation of crystalline glabridin into 
amorphous state. Then the peak would represent a glass transition peak with a small 
endothermic baseline shift and a relaxation peak. Whichever of the theories apply, this 
additional peak should not appear in an amorphously stabilized sample: If it is a melting peak 
of metastable crystalline glabridin the sample is partially crystalline, and if it represents a 
relaxation peak the amorphous glabridin is not sufficiently stabilized [24].  
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For the samples 6-25% and 6-50%, there are no further peaks in the range of 20-280 °C apart 
from the water peak at 100 °C (Figure 3). For sample 10-25%, however, the peak at 216 °C 
occurs identical to physical mixture. Therefore, this sample can be considered as overloaded, 
either with metastable crystalline glabridin or not sufficiently stabilized amorphous glabridin. 
For sample 17-25% both peaks are slightly shifted to lower temperatures probably because of 
partly reformed glabridin. Since a crystalline fraction demonstrably exists besides an 
amorphous fraction, this sample was excluded too. All other samples showed a clear melting 
peak of crystalline glabridin at 232 °C. Therefore, they were also excluded from further 
investigations.  
 
Figure 3: From upper to lower: DSC thermograms of the samples 6-25%, 6-50% and 10-25% showing no clear 
melting peak of glabridin at 232 °C, and 6-80% and 17-10% as examples for samples having a clear 
crystalline glabridin fraction visible by respective melting peak.  
Proof of amorphous state of glabridin by XRD diffractograms  
XRD is widely known as the standard method to characterize crystalline structures. Even if 
their sensitivity is below that of DSC measurements [17; 25], they allow a clear confirmation 
of amorphous phases by an amorphous halo. In contrast, DSC only proof the absence of a 
melting peak and thus crystallinity. Hence, the combination of DSC with XRD measurements 
seems reasonable.  
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The XRD measurements of promising samples (6-25%, 6-50%, 10-25%) were performed and 
the respective diffractograms are displayed in Figure 4. 
 
Figure 4: From upper to lower: XRD diffractograms of unloaded silica particles, glabridin raw drug powder, physical 
mixture at 1.5%, sample 6-50% and sample 10-25%.  
XRD diffractograms confirmed substantially the DSC results. For the silica particles, a broad 
amorphous halo was detected, being in accordance with the absence of melting peak in DSC 
thermogram. Same applies to the glabridin raw drug powder. Highly crystalline state without 
an amorphous halo was detected. Also, for the XRD measurements various ratios of physical 
mixtures were prepared and measured. The detection limit for XRD was determined to be 
1.5%. As already known, amorphous fraction can already be generated by preparing the 
physical mixtures. Therefore, the limit of detection (LOD) can possible be slightly below 1.5%. 
XRD diffractograms for sample 10-25% showed small peaks between 16 and 20 2Θ indicating 
the presence of small crystalline fractions about the LOD. But the sample 6-50% has been 
proven to be completely amorphous. Hence, a stable formulation with a high glabridin mass 
fraction of 37% can be produced.  
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Why did the above-mentioned rule “ratio <12” not applied? 
Silica were selected beforehand following the rule of pore size to molecule size ratio <12. The 
only exception was made for one silica, providing a ratio <20, being still promising for 
amorphization. However, results revealed, that glabridin was only completely amorphized 
using the silica Davisil® LC60A with a pore width of 6 nm.  
How can this observation be explained? For this study, only non-ordered silica were used. 
Compared to ordered silica [23], they have a wider pore size distribution [26]. Thus, the 
existence of pores exceeding the required ratio of <12 is possible and can be an explanation.  
Ordered silica were not used in this study, even though they provide a narrower pore size 
distribution. On the one hand they are not available in pharmaceutical grade up to now. Also, 
ordered silica are around 10-times more expensive than non-ordered silica. In combination 
with the high price of glabridin, the chance of entering the market seemed to be clearly 
lowered.  
To investigate if the assumption of broad pore width distribution is correct, further 
investigations were performed by nitrogen ad- and desorption.  
Localization of glabridin in the pores  
The nitrogen ad- and desorption technique is frequently used to measure the pore width as 
well as the volume and BET surface [19; 27]. Hence, this technique was used to measure the 
width of pore size distribution of used silica. The maximum pore size of the silica with declared 
mean pore size of 6 nm was 12 nm. This is still in the range of the required pore size to obtain 
molecule size ratio <12. In contrast, measurements of the silica Syloid® 72 FP with a declared 
pore size of 10 nm had a broad variation of 5-15 nm, exceeding indeed the needed ratio of 
<12. Thus, non-ordered silica with mean pore sizes should be selected with a sufficiently high 
safety margin to the maximum possible pore size. 
This method further allows the localization of glabridin within the sample. If for example the 
surface area increases after loading, the glabridin is primarily outside the silica and therefore 
not located in the pores. Also, Wei Q. et al. [14] reported, that the deposition of actives in the 
pores influences their release profiles. To give an insight on the deposition of glabridin in the 
pores hence allows the prediction of its release profile. For the prediction of glabridin release, 
its deposition was investigated for all 6 nm pore width samples as well as unloaded silica and 
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glabridin raw drug powder, both as references. The obtained results are all displayed in 
Figure 5.  
 
Figure 5: Left: Nitrogen ad- and desorption isotherms of unloaded silica, samples 6-25%, 6-50% and 6-80%, and 
glabridin raw drug powder. Right: Distribution of pore volume (dV(d)) and width determined after DFT 
method for respective isotherms.  
Unloaded silica shows a characteristic hysteresis loop [28] in H1 form (Figure 6, blue curves). 
This indicates cylindrically shaped pores of unloaded silica (Figure 6, upper right) [29]. After 
loading, the hysteresis loop did not change its form (Figure 6, purple curves). Thus, the 
cylindrical shape remains after loading, suggesting a filling by covering the pore surface evenly 
or a bottom to top filling. Since the pore width did not decrease with increasing loading 
(Figure 5, right), the second suggestion can be confirmed. 
Compared to a pore surface-covered loading, a slower release can be expected here [14]. 
However, the smartPearls are going to be used incorporated in vehicles. The release therefore 
is not that decisive as it was for Wei et al., focusing on oral administration.  
 

























































































































Why are none of the 80% loaded samples stable?  
With increasing loading, the BET surface [25] clearly decreased. Sample 6-25% has a 
BET surface of 412 m²/g, sample 6-50% a BET surface of 234 m²/g, and sample 6-80% a 
BET surface of only 66 m²/g. Also, the pore volumes according the DFT method [20] decreased 
with increasing loading from 0.53 mL/g to 0.25 mL/g and 0.17 mL/g, respectively. This means, 
that more than 1/3 (37%) of the pore volume is filled for the 6-25% sample. Also, the sample 
6-50% was more than expected 50% (almost 70%).  
This discrepancy certainly occurs because the density of the glabridin raw drug powder was 
used for the calculation of the theoretical loading of the pore volume, being crystalline. No 
amorphous glabridin was available for density determination, nor reported in literature. The 
different values of theoretical and real loading % suggests a higher density for amorphous 
glabridin by a factor of 1.4-1.5. Means, the theoretical loading of 80% corresponds to a 
practical/real loading of >100%. Therefore, all samples with theoretical loadings of 80% must 
be overloaded also confirmed by all measurements. 
6.3.3. Storage stability of glabridin smartPearls 
Physical storage stability assessed by XRD 
The special feature of smartPearls is the preservation of thermodynamically unstable 
amorphous state. Therefore, the physical stability of glabridin smartPearls was of outstanding 
interest for this study. XRD and DSC measurements were hence repeated after 2 and 7 months 
of storage at room temperature. The obtained diffractograms for the samples 6-25% and 




Figure 7: XRD diffractograms of 6-25% and 6-50% samples after 2 and 7 months of storage.  
Sample 6-25% remained completely in amorphous state after 7 months. In contrast, sample 
6-50% was only stable for 2 months as after 7 months (subsequent measurement point), re-
crystallization occurred. DSC thermograms underlined the XRD results. Hence, the loading of 
glabridin into the pores of the silica Davisil® LC60A enables the production and preservation 
of amorphous state until a theoretical pore volume loading of 25%. This corresponds to a 
glabridin mass fraction of 22.8% (w/w). Preservation of thermodynamically labile amorphous 
state is proved to be feasible by loading actives into suitable mesopores of silica particles.  
Chemical stability of glabridin assessed by HPLC 
In addition to the physical stability, the chemical stability of glabridin was investigated by HPLC 
directly after loading and after a storage time of 6 months – for the samples 6-25%, 6-50%, 
6-80% as well as 10-25% and 10-50%.  
Even though glabridin is known to be chemically sensitive in solutions and at higher 
temperatures, no degradation occurred during the loading process for all samples. Hence, the 
immersion-evaporation method used in this study presents a gentle method. This enables the 
loading of mesoporous particles with a broad spectrum of active.  

















After storing the samples for 6 months at room temperature without any special protection 
against oxygen or light, the mass fraction of glabridin for 6 nm pore samples slightly decreased 
by 2.4% in average. However, this reduction was statistically not significant and therefore 
negligible. Firm inclusion seemed to be connected to the chemical stability of loaded active. 
The 10 nm pore samples with greater tendencies for re-crystallization also showed the highest 
glabridin degradation of 4.7% among investigated samples, followed by sample 10-25% with 
3.1% glabridin degradation.  
For a general statement, that chemical stability can be increased by loading sensitive actives 
into mesopores, certainly not enough data were captured. However, this statement should be 
clarified in further studies.  
To sum up, glabridin smartPearls produced with 6 nm pore sized silica filled to 25% of total 
volume were stable physically and chemically for at least 6 months. Hence, a market feasible 
glabridin smartPearls formulation was successfully developed.  
6.3.4. Saturation solubility enhancement 
To prove the concept of enhanced saturation solubility for smartPearls, dissolution profiles 
were determined for freshly produced 6-25% sample and glabridin raw drug powder. 
Advantage of the Sirius system was, that the scattered light from unsolved particles were 
corrected. Hence, no remove of these particles was needed to obtain the pure absorption 
value of dissolved glabridin. 
Both profiles were generated over a period of 30 minutes. Within this time, no constant value 
was reached for both samples. Dissolution curve of smartPearls for example still slightly 
flattens (Figure 8, upper curve), where the curve of glabridin raw drug powder still slightly 
increases (Figure 8, lower curve). Thus, the “real” saturation solubility cannot be directly taken 
from the profiles and had to be calculated. Extrapolation according to the dissolution rate law 
of Noyes Whitney [30] were therefore applied, resulting in real saturation solubility of 
glabridin smartPearls of 6.8 µg/mL (coefficient of determination of 0.9912), and of glabridin 
raw drug powder of 1.6 µg/mL (coefficient of determination of 0.9977). Hence, the saturation 
solubility increased more than 4-fold. This demonstrates clearly that the concept of 





Figure 8: Dissolution profiles (left axis: absolute amount of dissolved glabridin (µg/mL) and right axis: relative 
amount of dissolved glabridin (m/m %)) over 30 minutes of glabridin smartPearls (black, sample 6-25%) 
and glabridin raw drug powder (red, RDP) obtained by in situ UV/VIS measurement. 
Unexpectedly, the dissolution profile of glabridin smartPearls showed a maximum at 9 µg/mL 
after 2 minutes. Then, glabridin concentration decreased slightly over time till a plateau at 
around 7 µg/mL is reached after 15 minutes. The maximum of 9 µg/mL represents most likely 
the saturation solubility of pure amorphous glabridin in smartPearls, leading to an 
oversaturated system with high internal energy. The surface of the silica seems to serve as a 
crystallization germ on which glabridin partially precipitates and lowers the internal energy. 
This is in good agreement with the turbidity remaining constant over measurement time and 
therefore excluding the formation of individual crystals. The precipitation on silica surface is 
fast and seems limited to a certain amount as the decreasing portion of curve is only from 
2-15 minutes. Thus, precipitation of glabridin on silica surface as small nm-sized crystals seems 
most plausible. As an amorphous part shall still be present in the silica, the real saturation 
solubility of 6.8 µg/mL seems to reflect a solubility equilibrium of the two existing forms. This 
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explains also why smartPearls are reported to be superior or at least as effective as 
nanocrystals.  
Notable is the quick reach of the maximum saturation (already after 2 minutes) for the 
smartPearls. In contrast, the maximum saturation for glabridin raw drug powder was not 
reached still after 30 minutes. Hence, by smartPearls not only the saturation solubility is 
increased, but also the dissolution velocity. This is important, since the glabridin smartPearls 
will be added as final step into an already prepared cream, lotion, or another dermal base. 
Hence, already during the incorporation process the full potential of glabridin is unfold, and 
no time is lost for interim storage.  
Both the increase in saturation solubility and dissolution velocity are highly favorable for the 
skin penetration. By the 4-fold increased saturation solubility, the concentration gradient 
between formulation and skin will be increased, leading to higher glabridin flux into skin. The 
higher dissolution rate is important to quickly replace the penetrated glabridin in the 
formulation. This will ensure that the concentration gradient being important for the flux is 
kept high for a long period. Hence glabridin penetration is improved by two increased 
parameters: saturation solubility and dissolution velocity.  
6.4. Conclusions 
Glabridin smartPearls were effectively produced by the immersion-evaporation method. By 
selected production parameters, pores were filled with glabridin from bottom to top. Most 
stable formulation was obtained by using Davisil® LC60A (6 nm pore width) with a theoretical 
pore volume filling of 25%. This corresponds to a high glabridin mass fraction of 23% (w/w) in 
final smartPearls formulation. Amorphous state of glabridin was preserved efficiently for 
7 months up to now. Hence, space restriction to suppress re-crystallization can be achieved 
efficiently by mesoporous silica particles with appropriate pore width. The concept of 
saturation solubility enhancement by smartPearls was proved. A more than 4-times higher 
saturation solubility was achieved by smartPearls compared to raw drug powder. Also, the 
dissolution velocity was distinctly improved. All these features of glabridin smartPearls makes 
them promising for skin care products with improved glabridin efficacy by simultaneously 
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Summary 
The first aim of this thesis was to summarize the existing knowledge in an overview, a “white 
paper” providing the scientific background (chapter 2). Covered are the historical 
development, intellectual property aspects (relevant for industrial products), mechanistic 
considerations and marketing aspects. Most important, the smartPearls technology was 
compared with the existing gold standard “nanocrystals” showing even better or at least 
similar penetration performance. smartPearls have the advantage of not being “nano”, which 
meets the increasing consumer expectation of having no “nano” ingredients in the products.  
The formulation challenge of µm-sized silica particles in fluid/semi-solid dermal formulations 
is the occurring sedimentation during storage. Increasing just the viscosity does not solve and 
delay the problem only. The second aim was therefore to develop physically stable, non-
sedimenting formulations (chapter 3). The problem was solved by generating viscoelastic 
formulations – transferring viscoelastic stabilization from food to pharma industry (e.g. salad 
dressing with herbs). i-carrageenan and polyacrylates were used as polymers – and as 
reference the polymer mixture from Kühne salad dressing. Gel properties were investigated 
by rotation rheology, amplitude sweep and a frequency sweep analysis. In addition, stability 
investigations with the LUMiSizer® were performed. From the overall data 3 years stability 
can be predicted. 
Third aim was to identify silica particles being optimal for loading with dermal actives 
(chapter 4 and 5). A variety of silica particles was investigated differing in particle size, pore 
size and pore volume. 
In chapter 4 avobenzone was used as model active, as it shows high crystallization tendency. 
Thus, it was a challenging molecule to prove the capability of smartPearls to preserve the 
amorphous state. Five different silica were used ranging in pore size from 3 to 25 nm, pore 
volume from 0.4 to 1.8 mL/kg and BET surface from 740 to 320 m2/g. Optimal were silica 
particles with 6 nm and 10 nm pore size. Long-term stability of 1 year could be shown. A 
mechanism of the pore loading process was suggested, pore filling takes place primarily from 
bottom to top (localization on pore walls contributes little to the loading). 
In chapter 5 rutin was used as model active, having high relevance for cosmetic products but 
also in dermopharmacy (anti-pollution strategy) at the same time. Rutin is poorly soluble and 
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shows little skin penetration. Optimal silica for loading with rutin were particles ranging in 
pore size from 6 nm to – in this case – 25 nm. The 6 nm pore particles have the advantage of 
a higher loading (25%, w/w), the 25 nm particles have a lower loading (18%, w/w) but a better 
processability. 
Within the fourth aim a loading process was optimized, which is scale-able to industrial scale. 
The immersion-evaporation method was applied and DMSO, the solvent used in previous 
studies was replaced by more skin-friendly ethanol. A mechanistic model was developed for 
the evaporation process, based on the Ostwald-Miers region. During the evaporation process, 
the concentration of dissolved active needs to remain within the Ostwald-Miers region. This 
can be controlled via evaporation temperature and vacuum applied to the rotary evaporator. 
For up-scaling the evaporation velocity needs to be adjusted to be in the same range as in the 
used smaller rotary evaporator. This process optimized should allow medium sized cosmetic 
companies to produce products based on smartPearls. 
Within the final aim, the acquired knowledge was used to ensure more efficient formulations 
with the challenging cosmetic active glabridin – highly effective whitening agent (chapter 6). 
It is poorly soluble, even applying it in a high concentration on the skin (suspension 
formulation) will not significantly improve its penetration. smartPearls are therefore an 
enabling technology for improving penetration into the skin by increasing the saturation 
solubility. Various pore-sized silica were investigated. Optimal were the silica particles with 
6 nm pore size at 25% loading of the pore volume. Stability over 7 months was shown of the 
powdered silica. Glabridin has a high price (10,000 USD/kg), thus a formulation principle 
requiring very low concentrations of active is necessary and can be provided by smartPearls. 
In overall the state of the art of smartPearls has been reviewed within this thesis. Physically 
stable dermal formulations were developed, based on viscoelasticity. Thus, one essential pre-
requisite for use as dermal product was fulfilled. Ideal silica particles for loading were 
identified, using model actives avobenzone and rutin. Large scale production – another pre-
requisite for use as dermal product – is now feasible based on the optimized immersion 
evaporation process. For better academic understanding mechanisms for the loading process 
(pore filling) and loading evaporation process (Ostwald-Miers based theory) were identified. 
Finally, the acquired knowledge was used for the formulation of a market relevant molecule 
in cosmetics and pharmacy – glabridin. 
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Zusammenfassung 
Erstes Ziel dieser Arbeit war es, das vorhandene Wissen in einem Überblick 
zusammenzufassen, einem sogenannten "White Paper", das den wissenschaftlichen 
Hintergrund bildet (Kapitel 2). Betrachtet werden die historische Entwicklung, Aspekte des 
geistigen Eigentums (relevant für Industrieprodukte), mechanistische Überlegungen und 
Marketingaspekte. Die smartPearls-Technologie wurde mit dem bestehenden Goldstandard 
"Nanokristalle" verglichen. Dabei konnte gezeigt werden, dass smartPearls eine noch bessere 
oder zumindest ähnliche Penetrationsperformance zeigen. smartPearls haben den Vorteil, 
dass sie keine „nano“-Produkte sind und somit die steigende Kundenerwartung an Produkte 
ohne „nano“ Inhaltsstoffe erfüllen.  
Die Herausforderung bei der Formulierung von µm-großen Silica Partikeln in 
flüssigen/semifesten dermalen Formulierungen ist die auftretende Sedimentation während 
der Lagerung. Eine alleinige Erhöhung der Viskosität löst das Problem nicht, sondern verzögert 
nur die Sedimentation. Das zweite Ziel war daher die Entwicklung physikalisch stabiler, nicht 
sedimentierender Formulierungen (Kapitel 3). Das Problem wurde durch die Entwicklung 
viskoelastischer Formulierungen gelöst. Die viskoelastischen Stabilisierung wurde von der 
Lebensmittelindustrie auf die Pharmaindustrie übertragen. Als Polymere wurden Carragenaan 
und Polyacrylate verwendet und als Referenz die Polymermischung aus dem Kühne 
Salatdressing. Die Gel-Eigenschaften wurden durch Rotationsrheologie, Amplituden-Sweep 
und eine Frequenz-Sweep-Analyse untersucht. Darüber hinaus wurden 
Stabilitätsuntersuchungen mit dem LUMiSizer® durchgeführt. Aus den Gesamtdaten können 
mindestens 3 Jahre Stabilität vorhergesagt werden. 
Als drittes Ziel sollten Silica-Partikel identifiziert werden, die optimal für die Beladung mit 
dermalen Wirkstoffen sind (Kapitel 4 und 5). Eine Vielzahl von Silica-Partikeln die sich in 
Partikelgröße, Porengröße und Porenvolumen unterscheiden, wurde untersucht. 
In Kapitel 4 wurde Avobenzon, ein UV Blocker mit hoher Kristallisationstendenz, als 
Modellwirkstoff verwendet. Fünf verschiedene Silica mit Porengrößen von 3 bis 25 nm, 
Porenvolumen von 0,4 bis 1,8 mL/kg und BET-Oberfläche von 740 bis 320 m2/g wurden 
eingesetzt. Optimal waren Silica-Partikel mit 6 nm und 10 nm Porengröße. Es konnte eine 
Langzeitstabilität von einem Jahr nachgewiesen werden. Es wurde ein Mechanismus zum 
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Ablauf des Beladungsprozesses vorgeschlagen, die Porenfüllung erfolgt demnach primär von 
unten nach oben. Wirkstoff-Lokalisierung an den Porenwänden trägt wenig zur prozentualen 
Belastung bei. 
In Kapitel 5 wurde Rutin als Modellwirkstoff eingesetzt, das gleichzeitig eine hohe Relevanz 
für Kosmetikprodukte, aber auch für die Dermopharmazie (Antipollutionsstrategie) hat. Rutin 
ist schwer löslich und weist eine geringe Hautpenetration auf. Optimale Silica für die Beladung 
waren Partikel im Bereich von 6 nm bis – in diesem Fall – 25 nm Porengröße. Die 6 nm 
Porenpartikel haben den Vorteil einer höheren Belastung (25%, w/w), die 25 nm Partikel 
haben eine geringere Beladung (18%, w/w), dafür aber eine bessere Prozessierbarkeit. 
Im Rahmen des vierten Ziels wurde ein Beladungsprozess optimiert, der im industriellen 
Maßstab skalierbar ist. Es wurde die Immersions-Evaporations-Methode angewendet, das 
bisher verwendete Lösungsmittel DMSO wurde durch Ethanol ersetzt. Für den 
Verdampfungsprozess wurde ein mechanistisches Modell auf Basis des Ostwald-Miers 
Bereiches entwickelt. Während des Verdampfungsprozesses muss die Konzentration der 
gelösten Wirkstoffe innerhalb des Ostwald-Miers Bereiches bleiben. Dies kann über die 
Verdampfungstemperatur und das am Rotationsverdampfer anliegende Vakuum gesteuert 
werden. Für die Hochskalierung muss die Verdampfungsgeschwindigkeit angepasst werden, 
um im gleichen Bereich zu liegen wie bei dem verwendeten, kleineren Rotationsverdampfer. 
Dieser optimierte Prozess ermöglicht es, mittelständischen Kosmetikunternehmen Produkte 
auf Basis von smartPearls herzustellen. 
Das erworbene Wissen wurde für die Formulierung des anspruchsvollen kosmetisch Wirkstoff 
Glabridin, ein hochwirksamer Melanininhibitor zur Hautaufhellung, angewendet (Kapitel 6). 
Es ist schwer löslich, auch in hoher Konzentration auf die Haut aufgetragen 
(Suspensionsformulierung), wird seine Penetration nicht wesentlich verbessert. smartPearls 
sind durch Erhöhung der Sättigungslöslichkeit ein möglicher Ansatz zur Verbesserung der 
Penetration von Glabridin in die Haut. Es wurden verschiedenporige Silica untersucht. Optimal 
waren die Silica-Partikel mit 6 nm Porengröße bei 25%iger Beladung des Porenvolumens. Die 
Stabilität der pulverförmigen Silica wurde über 7 Monate nachgewiesen. Der hohe Preis von 




Innerhalb dieser Arbeit, wurde der Stand der Technik von smartPearls zusammengefasst. 
Physikalisch stabile dermale Formulierungen, die auf Viskoelastizität basieren, wurden 
entwickelt. Damit wurde eine wesentliche Voraussetzung für die Verwendung in dermalen 
Produkten erfüllt. Unter Verwendung der Modellwirkstoffe Avobenzon und Rutin wurden 
optimale Silica-Partikel für die Beladung identifiziert. Durch den optimierten Immersions-
Evaporations-Prozess ist die Skalierung möglich. Zum besseren akademischen Verständnis 
wurden Mechanismen für den Ladeprozess (Porenfüllung) und den Verdampfungsprozess 
(Theorie basierend auf dem Ostwald-Miers Bereich) identifiziert. Das erworbene Wissen 
wurde für die Formulierung eines marktrelevanten Moleküls in Kosmetik und Pharmazie 
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